A runtime alterable epidemic model with genetic drift, waning immunity, and vaccinations

Wayne M. Getz[1,2,3], Richard Salter[3,4], Ludovica Luisa Vissat[1],
James S. Koopman[5,6], Carl P. Simon[6,7,8]

[1]Dept. ESPM, UC Berkeley, CA 94720-3114, USA

[2]School of Mathematical Sciences, University of KwaZulu-Natal, South Africa

[3]Numerus, 850 Iron Point Rd., Folsom, CA 95630, USA

[4]Computer Science Dept., Oberlin College, Oberlin, Ohio, OH 44074, USA

[5]School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA

[6]Center for the Study of Complex Systems, University of Michigan, Ann Arbor, MI 48109, USA

[7]Gerald R. Ford School of Public Policy, University of Michigan, Ann Arbor, MI 48109, USA

[8]Department of Mathematics, University of Michigan, Ann Arbor, MI 48109, USA

Corresponding Author: Wayne M. Getz, wgetz@berkeley.edu

Author Contributions: JSK and CPS initiated the project, provided feedback on early drafts and participated in discussions. WMG designed and formulated the M-SEIR IBM model, drafted the manuscript, ran simulations, and produced the figures. RS designed and built the RAMP platform and wrote the code and informational text. LLV checked all the mathematical equations and code. Both RS and LLV contributed to the structure of the manuscript. All authors contributed to editing and adding text as needed.

Competing Interest Statements: none

Keywords: SEIR models, Individual-based models, escape mutations, RAMPs, SARS-CoV-2, variant dynamics

1 Abstract

In this paper, we present methods for building a Java Runtime-Alterable-Model
Platform (RAMP) of complex dynamical systems. We illustrate our methods by
building a multivariant SEIR (epidemic) RAMP. Underlying our RAMP is an
individual-based model that includes adaptive contact rates, pathogen genetic
drift, waning and cross immunity. Besides allowing parameter values, process
descriptions, and scriptable runtime drivers to be easily modified during simula-
tions, our RAMP is easily integrated into other computational platforms, such
as our illustrated example with R-Studio. Processes descriptions that can be
runtime altered within our SEIR RAMP include pathogen variant-dependent
host shedding, environmental persistence, host transmission, and within-host
pathogen mutation and replication. They also include adaptive social distanc-
ing and adaptive application of vaccination rates and variant-valency of vaccines.
We present simulation results using parameter values and process descriptions
relevant to the current COVID-19 pandemic. Our results suggest that if wan-
ing immunity outpaces vaccination rates, then vaccination rollouts may fail
to contain the most transmissible variants, particularly if vaccine valencies do
not adapt to escape mutations. Our SEIR RAMP is designed for easy-use by
individuals and groups involved in formulating social-distancing and adaptive
vaccination rollout policies. More generally, our RAMP concept facilitates con-
struction of highly flexible complex systems models of all types, which can then
be easily shared among researchers and policymakers as stand alone applications
programs.

1   Introduction

Kermack and McKendrick pioneered the application of differential equations to modeling the dynamics of disease systems that included susceptible (S), infected/infectious (E/I) and recovered (R, we use V to include vaccinated) classes of individuals [1]. Subsequent extensions of their formulation include, *inter alia*, additional disease and demographic classes [2], multihost and pathogen strain considerations [3,4], spatial heterogeneity [5,6], network [7] and individual-based formulations [8,9]. Along with these extensions has come the challenge of "not being able to see the forest for the trees" when questions beyond those pertaining to the profiles of epidemics on homogeneous, well-mixed, large populations arise. As with the current COVID-19 pandemic, these questions may relate to the emergence of new pathogen variants [10], the effects of waning and cross-immunity in hosts with different exposure histories to these variants [11], differential transmission and virulence of these variants, issues of spatial heterogeneity and host heterogeneity related to age, gender, and health status factors [12].

We only have the capacity from both technology and human comprehension points of view to understand at any one time how a limited number of factors may explain or affect epidemiological outcomes when measures are applied to mitigate the severity of disease outbreaks. Thus, we are brought to consider the issue of how to craft a model so that it has the "appropriate level of complexity" to address the questions at hand [13,14]. We otherwise follow Einstein's dictum that "models should be as simple as possible, but no simpler."

To facilitate the processes of both "incorporating complexity into" and "stripping complexity out of" models, we have developed the concept of a Runtime Alterable Model Platform (RAMP). This allow us to focus on outcomes rather than on the logistics of modifying and coding models and carrying out comparative analyses. Our RAMP includes panels, windows and sliders that allow users to specify and manipulate model parameter values, modify process function descriptions, and scripting drivers for implementing sets of simulations. Further, modifications can be made both at the start of and during the course of a simulation, while protecting the integrity of the underlying code. In addition, our RAMP automates documentation of all parameter values, process descriptions, changes and actions (modifications and substitutions during simulation) in a file that is then saved at the end of each simulation. This file is then ready for later comparative analyses across sets of simulations, or within data processing environment that incorporate our RAMP as a component package, such as R-Studio.

RAMPs can be developed for models that address classes of problems, formulated using a Goldilocks principle. Thus, these classes should not be too general so that comparisons within each class require extensive alterations to models (members of the class should share significant structural properties with regard to process dynamics), but also not too specialized so that comparisons across members of the class are too limited to provide answers to question of interest. Thus we might develop different RAMPs to study genetic, morphogentics, epidemiological, evolutionary, geological, and environmental processes.

Here we provide an example of a RAMP that has sufficient breadth to investigate an array of questions pertaining to multivariant epidemiological dynam-

ics for directly transmissible diseases, such as the current SARS-CoV-2 pan-
demic [15,16], influenza [17], or Ebola [13,18]. For simplicity, we refer to this as
our M-SEIR (multivariant susceptible-exposed-infected-recovered) RAMP. For
the study of water-borne or vector-borne diseases, similar but somewhat more
complicated RAMPs will need to be developed. Our M-SEIR RAMP is designed
to be used by individuals either with no coding skills, or with minimal coding
skills if they desire to modify some of the process descriptions incorporated into
the supplied platform. It is sufficiently detailed, however, to allow the user to
incorporate either supplied or user-altered versions of the following processes: i)
pathogen variant-specific shedding [19], environmental persistence [20], within-
host replication [21] and mortality rates [22]; ii) immunological waning with
variant cross immunity [23, 24]; iii) pathogen variant drift during transmission
and within-host replication [25]; iv) an adaptive contact rate [26]; v.) a time-
dependent, uni- or multivalent vaccine rollout [27, 28] (Fig. 1; for mathematical
details see Materials and Methods, as well as our Supplementary Online File—
here forth referred to as SOF—Appendix A).

Figure 1: An overview of the processes included in our M-SEIR model (see Table 1 for equation references.) The probability $\pi_{ih,jl}^{\text{inf}}$ of A_h being infected primarily with pathogen ℓ in terms of receiving an effective dose from agent A_i is computed in terms of a concatenation of shedding rates ($\zeta_{i\ell}$), environmental persistence rates (η_ℓ), and host transmission ($\beta_{h\ell}$) processes (SOF Eq. A.12) and includes both waning and cross immunity factors. The probability $\pi_{h\ell\ell'}^{\text{inv}}$ that the dominant variant emerging in host A_h is variant ℓ' given initial infection with variant ℓ is computed in terms of within-host mutation and within-host replication process (SOF Eq. A.13) and also includes both waning and cross immunity factors. These two probabilities are then used to compute the overall probability $\pi_{ih,j\ell'}$ (SOF Eq. A.14) that infector i, infected with major variant j, infects infectee h with major variant ℓ'. The quantity $R_{\text{eff}}(t')$ is the expected number of individuals each infectious agent is expected to infect around time $t' \in [t + \sigma_E, t + \sigma_E + \sigma_I]$, where $R_0 = R_{\text{eff}}(0)$ is estimated for our model using SOF Eq. A.26.

87   The reason for our inclusion of an adaptive contact rate process is that

the local nature of contact rate patterns is well established as an important driver of outbreak dynamics [15]. If contact rates remain unchanged during the course of an epidemic, then a classic incidence curve (as in Fig. 2) will be the result. However, repeated peaks associated with consecutive outbreak waves arise as a results of implementing and then relaxing social distancing measures [15]. In the absence of social distancing drivers, which vary greatly from one location/region/country to another, an automated way to evaluate the effects of social distancing measures is through an adaptive contact process of the type that we include in our M-SEIR RAMP.

To illustrate the application of our M-SEIR RAMP, we used it to explore aspects of disease incidence and prevalence profiles using parameters that are applicable to the SARS-CoV-2 pathogen at the start of the COVID-19 pandemic. For example, we compare constant and adaptive (viz., prevalence dependent) contact rate processes under different waning immunity scenarios. We also explore the emergence of variants for different mutation and variant transmission rates. Additionally, we show how our M-SEIR RAMP can be used to evaluate the efficacy of uni- and multivalent vaccines applied at various time-dependent rates, where choice of valency may switch in response to realtime monitoring and surveillance data. Such adaptive vaccination programs may be required to combat the evolutionary arms race between vaccine efficacy and the evolution of new pathogen variants [25, 28, 29]. We hope, however, that our results and subsequent investigations using our M-SEIR RAMP provide the kinds of quantitative analyses that can help formulate highly effective local or country level vaccination programs that avoid some of the vaccination rollout pitfalls revealed by our analysis, as well as encourage the adoption of effective adaptive vaccination programs.

2   Materials and Methods

2.1   Our M-SEIR in a nutshell

We constructed an individual-based model (IBM) of a susceptible-exposed-infectious-recovered (i.e., an SEIVD model, where removed R are split into V=immune/vaccinated, and D=dead) epidemiological process [30, 31] in a homogeneous population with a random encounter contact rate parameter $\kappa_0 > 0$. Our formulation allows for the emergence of multiple variants of the pathogen during a concatenation of process depicted in Figure 1 and listed in Table 1. Specifically, our formulation includes a host immunological waning process [23, 32] and a mutational process that impacts both transmission of mutant variants from the infectee and genetic drift [11, 24, 33] of variants within the infector, with rates impacted by cross immunity effects. We also allowed for variation in pathogen variant transmissibility (i.e., in the $\beta > 0$ parameter of the frequency dependent transmission function $\beta SI/N$ [34, 35]) and pathogen virulence as represented by the disease-induced host mortality rate in the sense of Anderson and May [36] (and often represented by a parameter $\alpha \geq 0$ [34]).

The detailed formulation of our model and its algorithmic implementation is provided in Appendix A (SOF), with references to relevant equations in this provided in Table 1. In a nutshell we:

1. defined a set of 2^J pathogen variants (user selected value for variant entropy J ranging from 0 to 7; pathogen index $j = 0, ..., 2^J - 1$) with a genetic-relatedness topology of a J-dimensional unit cube—i.e., each pathogen has J-loci that can take on one of two allelic values at each locus with immediate neighboring variants differing from each other by exactly one allelic value (0 or 1) at only one of the J loci

2. defined a population of N_0 hosts as belonging at time t to either an epidemiologically naïve set of susceptible individuals **S** of size $N_S(t)$, a set **A** of $N_A(t)$ identified agents A_i $(i = 1, ..., N_A(t))$ whose epidemiological histories are known, or a set **D** of $N_D(t)$ individuals that have died from the disease

3. allowed pathogen variant-specific transmission "force" ($\bar{\beta}_j > 0$) and virulence ($\alpha_j \geq 0$) parameters to vary in value among one another within a defined range $\bar{\beta}_j \in [\beta_{\min}, \beta_{\max}]$ and $\alpha_j \in [\alpha_{\min}, \alpha_{\max}]$

4. kept track of the total prevalence N_I as the sum of the prevalences of the individual variants N_{I_j}, $j = 0, ..., 2^J - 1$—i.e. $N_I = \sum_{j=0}^{2^J-1} N_{I_j}$

5. introduced a random contact rate function $\kappa(t)$ with a constant parameter κ_0 that is Poisson distributed on $[t, t+1)$, $t = 0, 1, \cdots$, multiplied by an adaptive response function that reduces the contact rate with increasing disease prevalence, such that the $\kappa(t)$ is reduced to $\kappa_0/2$ when the $N_I(t)/(N_0 - N_D) = p_I^{\text{half}}$—see SOF Eq. A.7

6. updated the epidemiological state of the agents A_i with respect to each of the variants $j = 0, ..., 2^J - 1$, where the state with respect to particular variant j at time t is represented by a list that includes the following J entries pertain to the state of A_i with respect to pathogen variant $j = 0, ..., 2^J - 1$. If the jth entry is:

    (a) 0, then agent A_i has never been infected with this variant

    (b) $E_j(t, \tau_{ij})$, was infected at time $\tau_{ij} \leq t$ with this variant, but is not yet infectious for an expected period of σ_E units of time

    (c) $I_j(t, \tau_{ij})$, then agent A_i was infectious at time t with this variant, for an expected period of σ_I units of time, having been most recently infected (reinfections with the same variant may occur) with this variant at time $\tau_{ij} < t$

    (d) $V_j(t, \tau_{ij})$, then agent A_i has now recovered from its most recent infection at time τ_{ij} with this variant and has some level of waning immunity to it

7. assumed that agent A_i can be infectious at time t with at most one dominant variant (denoted by the index j), although due to mutational processes this agent may infect other agents with variants related to this dominant variant at much lower rates (i.e., through application of a mutation factor $\mu << 1$, applied in our basic model through Eq. A.13)

8. assumed that agent A_i will have different levels of waning immunity to all of the variants to which it has been infected in the past

9. included waning immunity functions $\omega_{ij}(t)$ (symbol is omega: SOF Eq. A.6) used to compute the level of immunity that agent A_i has to its most recent infection by variant j

10. included cross immunity effects (a J^2-matrix C) that apply both to the *infector* transmitting the pathogen and the *infectee* being invaded (inv; its

"airport code" as described in SOF Fig. B.3) by the pathogen of interest, both of which reduce the likelihood of infection and variant drift by variant j compared with closely related variants ℓ (for a simple example of the matrix C, see Eq. 1 in Section 3 below)

11. computed an *infection probability* $\pi_{ih,j\ell}^{\text{inf}}$ that agent A_i infected with variant j infects agent A_h with variant ℓ in terms of a concatenation of infector viral shedding ($\zeta_{i\ell}$; for a simple example see Eq. 6 in Section 3 below), viral persistence in the environment (η_ℓ), and viral transmission ($\beta_{h\ell}$) processes (Fig. 1)

12. computed an *invasion probability* $\pi_{h\ell\ell'}^{\text{inv}}$ that an agent A_h infected with variant ℓ becomes infectious with variant ℓ' as its major variant, in terms of the multiplicative effects of viral mutation (μ) and replication (λ_ℓ) processes ongoing within an infectee A_h during this infectees exposed ($E_{\ell'\tau_{h\ell'}}$) and infectious ($I_{\ell'\tau_{h\ell'}}$) periods (Fig. 1)

13. computed the overall probability $\pi_{ih,j\ell'}$ that an infector A_i infected with major variant j results in an infectee A_h expressing ℓ' as its major variant

14. assumed that waning and cross immunity to a particular variant is the same for both natural infections and vaccinations that use the antigen associated with that variant (of course we can easily extend our model to remove this assumption once data become available to support different waning and cross immunity rates for natural infections and particular vaccines)

15. implemented a discrete time individual-based stochastic SEIVD (here V represents individuals that have either recovered from infection or have been vaccinated, D represents cumulative dead; also see [37]) multivariant model that includes specifiable time-dependent univalent and multivalent vaccination implementations

2.2   Our RAMP implementation

Models of systems process can be coded as singular implementations model formulations using: i) highly efficiently compilable computer languages (e.g., C++, FORTRAN, Java); or ii) less efficiently, but more easily coded, scriptable (e.g., JavaScript, Python, Perl) computer languages. More conveniently and expeditiously, they can be coded up, as discussed in [38], using a systems modeling platform, such as Matlab's SIMULINK, Mathematica, Stella, AnyLogic, Numerus, or Berkeley Madonna. Advantages of the latter include more rapid and accurate model development, though simulations may be slowed down by platform overhead. Between these extremes, we propose a more general approach to specific classes of systems' models, where the basic system structure is fixed, but implementation of some elements can be easily and safely altered so that optional implementations are presented at runtime. We call such a design *runtime alterable-model platforms.* (RAMPs); and here we present a Java RAMP implementation of the M-SEIR described in the previous subsection.

The characteristics we envision for a model platform to be a RAMP are:

1. RAMPs include a set of model parameters (constants) whose values can be selected or specified (sometimes within a predefined range of values)

Table 1: Variables, indices and functions in our M-SEIR RAMP

Symbols	Variables and indices	Equation (See SOF)
Variables		
t	time (variable and function values depend on time)	
N_{S}, N_{A}, N_{D}	size of sets **S**, **A** and **D**	Eq. A.1
J, j, m, ℓ and ℓ'	variant entropy and indices $(0, ..., 2^J - 1)$	Eq. A.2
N_{I}, N_{I_j}	total and variant j infectious class size	
A_i, A_h	specific agents $i, h = 1, ..., N_{\mathrm{A}}(t)$ in set **A**	Eq. A.4
Functions (if a parameter now it may be elaborated later as a function)		
κ	adaptive contact rate	Eq. A.7
ω_{ij}	waning immunity of A_i w.r.t. variant j	Eq. A.6
c_{mj}	cross immunity encountered by variant j when agent previously infected with variant m	Eq. A.8
ϕ_{ij}	immunity modifier	Eq. A.8
ζ_{ij}	shedding rate of variant j by infector A_i	Eq. A.9
η_ℓ	environmental persistence	Eq. A.10
$\beta_{h\ell}$	variant transmission to infectee A_h	Eq. A.11
$\pi_{ih,j\ell}^{\mathrm{inf}}$	probability A_i infects A_h	Eq. A.12
μ	mutation process factor	Eq. A.13
$\lambda_{\ell'}$	within-host replication rate	Eq. A.13
$\pi_{h\ell\ell'}^{\mathrm{inv}}$	probability ℓ' is major variant when ℓ invades	Eq. A.13
$\pi_{ih,j\ell'}$	probability ℓ' is major variant in A_h when j is major variant in A_i	Eq. A.14

at simulation runtime using a switch, nob, slider, or text-entry window
accessed via a platform graphical interface or dashboard (e.g., see Fig. 2
and Table 1 which apply to our M-SEIR RAMP).

2. RAMPs include a specific set of *runtime alternative modules*, (RAMs),
where the original can be redefined in a graphical interface window, and
the unaltered original and the alternative routines are stored as a (prefer-
ably open-ended) numbered set. The original or any one of the alternatives
can be selected for use at runtime (for a list of functions in our RAMP
see Table 2).

3. RAMP implementations also provide an API for both remote and on-
board scripting. This API enables control of all user aspects of the simu-
lation, including the parameter set, run management, RAM options, and
data retrieval. Script logic can alter parameter settings and RAM options
as the simulation progresses. A Nashorn-based Javascript interpreter en-
hanced with API methods is provided.

4. The API can be accessed remotely using operating system facilities by
external applications running concurrently with the simulator. Of partic-
ular interest is the ability to control the simulation from the R statistical
platform. An R routine can be formulated to both manage the simulation
run and to retrieve and process the resulting data. The RAMP simulation

becomes a "virtual package" to the controlling R logic. See SOF Appendix B.

We implemented our RAMP using Java and made ample use of all of the features described above. Use of the RAM facility permitted experimentation with the several versions of cross immunity (e.g., Eqs.1 and 2). A Javascript program was used to control an adaptive vaccination strategy. A small R package serving as a driver was used in an R program that ran the simulations multiple times, extracted results into R data structures, and produced graphs showing statistical mean and standard deviation. More details on the graphical structure and implementation of our M-SEIR are provided in the presentation of both the results below and information in SOF Appendix B.

2.3 Simplifications and Running the model

In the examples presented in the next section, we have not taken advantage of the full complexity of the model. Thus, for example, in our multivariant simulations we have assumed that all variants are shed at the same relative rate (i.e., $\zeta_{ij} = 1$ for relevant i and $j = 0, ..., 2^J - 1$) , have the same environmental persistence properties (i.e., $\eta_\ell = 1$ for all $\ell = 0, ..., 2^J - 1$), the same within host replication rates (i.e., $\lambda_{\ell'} = 1$ for all $\ell' = 0, ..., 2^J - 1$), and are all equally virulent (i.e., $\alpha_j = \alpha$ for all $j = 0, ..., 2^J - 1$). Obviously, these assumptions can be relaxed once suitable data are available for a particular pathogen to support variant specific shedding, persistence, within-host replication, and virulence values.

Further, in the absence of the kind of cross-immunity data obtained from cross-neutralization studies to be able to fit values to the cross-immunity parameters c_{mj} in the cross-immunity matrix $\mathbf{C}$ we contrast the following two cross-immunity scenarios with respect to a global cross-immunity constant $c \in (0, 1)$. The first we call *cascading* cross-immunity since the level of cross-immunity diminishes multiplicatively with genetic distance of the two strains: viz.

$$\text{Cascading } \mathbf{C}: \qquad c_{mj} = \left\{ \begin{array}{ll} 1 & \text{if } j = m \\ c^k & \text{if } j \text{ differs from } m \text{ by } k \text{ alleles} \end{array} \right. \tag{1}$$

The second we call *escaping* cross-immunity since when the final allele in the array of J loci mutates from 0 to 1, it escapes completely from cross neutralization effects with all strains that have the original allele at the Jth locus: viz.

$$\text{Escaping } \mathbf{C}: \qquad c_{mj} = \left\{ \begin{array}{ll} 1 & \text{if } j = m \\ 0 & \text{if } j \geq 2^{J-1} \text{ and } \ell < 2^J \text{ provided } J > 2 \\ c^k & \text{otherwise, where } j \text{ differs from } m \text{ by } k \text{ alleles} \end{array} \right. \tag{2}$$

Obviously, this is an idealization of the *escape mutation* phenomenon, which we set up here to enable us to evaluate behavior of such mutations. For the purposes of this paper, idealized escape mutations are defined as those whose level of cross-immunity with the variants from which they arise is 0 (in reality some small level of cross immunity may remain).

Also, in the absence of comprehensive data that allows us to use realistic estimates for the relative transmissibility β_j and virulence α_j of various variants

285 $j = 0, ..., J$, we employ the following scenario facilitating formulations. These
286 permit us to investigate the potential impacts of increased transmission and
287 virulence with the emergence of new strains based on the number of mutations
288 d_j needed to get from variant 0 to variant j. Specifically, for

$$d_j = \text{Hamming distance between variants 0 and } j \tag{3}$$

289 and for transmissibility and virulence perturbation parameters δ_β and δ_α re-
290 spectively, we define

$$\text{Transmissibility:} \qquad \bar{\beta}_j = \beta(1 + \delta_\beta)^{d_j} \tag{4}$$

291 (the bar notation here reminds us that this value is used in the computation of
292 β_{ij} according to equation Eq. A.8) and

$$\text{Virulence:} \qquad p_{\alpha_j} = p_{\alpha_j}(1 + \delta_\alpha)^{d_j} \tag{5}$$

293 (this is a probability rather than a rate and we have to ensure δ_α is selected
294 such that $p_{\alpha_j}(1 + \delta_\alpha)^J \leq 1$).
295   Also for simplicity's sake we assumed that infectee with major variant j will
296 shed minor variants in the immediate neighborhood of j at comparative rate
297 $\zeta \in [0, 1)$ and be major variant-independent: i.e., we assumed

$$\text{Shedding:} \qquad \zeta_{j\ell} = \left\{ \begin{array}{ll} 1 & \text{if } \ell = j \\ \zeta & \text{if } \ell \text{ differs from } j \text{ by one allele} \\ 0 & \text{otherwise} \end{array} \right. \tag{6}$$

298 Finally, in this paper we will not investigate any seasonal effects, which is equiv-
299 alent to setting $\delta_{\text{season}} = 0$ in Eq. A.10, and using this setting in all our simula-
300 tion.
301   The model itself can be accessed at Github, where instructions are available
302 for launching and using our SEIVAgent application.

Figure 2: **A.** The dashboard of our Java Runtime-Alterable-Model Platform (RAMP) SEIVD (S=susceptibles, E=exposed, I=infectious, V=immune, D=dead) individual-based model (IBM) and simulations obtained using the parameters values depicted in the slider windows (also see Table 2). The top left window of this dashboard contains information on the final state of the population (in this case $S = 3898$ and $D = 143$ in a population of $N_0 = 10,000$), the bottom left bar graph of dashboard panel is the final values of E, I, V and D at epidemic cessation at time $t = 166$ (days) or the simulation run time, whichever comes first. Dashboard also shows a graph of incidence (purple: selected using colored buttons below the graph). The bottom ribbon of the dash board has a series of radio buttons that respectively open a Log, a JavaScript (JS), and a Scripting (S) window, Line and Bar graph windows (for multivariant runs), as well as windows for controlling vaccination strategies (V), listing realtime agent information (A), pathogen parameter values (P), monitoring probability computations (Intern), coding and controlling runtime alternative operations (Op), and three runtime buttons (Reset, Step, Run). **B.** Graphs of prevalence and cumulative deaths (cut out from main panel when only the red and black buttons are on) and **C.** daily deaths (crimson button) are pasted below the dashboard.

3   Illustrative Examples

3.1   Single variant simulations

Parameter values and baseline run

The first variable that needs to be determined is the unit of time we use for our simulations because all process rate parameters are scaled by its selection. Since the time resolution of empirical COVID-19 incidence and mortality data is daily, we selected our unit of time t to be days. Additionally, based on various sources including a metapopulation study of COVID-19 parameter estimates [39], we set the latent and infectious periods to be 4 and 7 days respectively. Basic SEIR epidemiological models do not separate out the processes of contact and transmission-per-contact, so we had some leeway on what values to choose for contact rates and transmission rates per contact because it is the value of the product of these that is important in determining the reproductive value, commonly referred to as "R_0" for COVID-19. Hussein et al.'s [39] meta analysis of COVID-19 zeroed in on $R_0 = 3.14$ as a mean value across a range of studies (95% confidence interval $[2.69, 3.59]$). By setting our baseline contact rate and transmission parameters to be $\kappa_0 = 3$ and $\beta = 0.3$, we estimated the value of R_0 in our model to be approximately $R_0 = 3.1$. These and the remaining values of the parameters used in our simulations are summarized in Table 2.

Adaptive contact rate

None of the major outbreaks of COVID-19 around the world followed a classic "rise-and-fall" incidence curve because of social distancing and other measures taken to mitigate transmission once it had been determined that a full-blown outbreak was underway. These measures waxed and waned with government regulations and the perception that the outbreak was respectively under or out of control. This, in turn, resulted in incidence profiles that rose and fell multiple times (i.e., so-called waves) as these measures waxed and waned. Thus, it is not possible to replicate the incidence curves of any of the country/regional epidemics without characterizing the social distance and subsequent social relaxation measures driving their rise and fall [15].

In a general way, we can capture the gestalt effects of this kind of social behavior by assuming the contact rate $\kappa(t)$ is influenced by current or recent prevalence levels, where current prevalence is given by the ratio of the number of infected individuals $N_I(t)$ to current population size $N(t) - N_D(t)$. Thus, in the various scenarios present below, we assume an adaptive response rate that has a maximum value κ_0 when $I(t) = 0$ and is reduced to half this value, as a declining sigmoidal curve specified in Eq. A.7, when $\frac{N_I(t)}{N(t) - N_D(t)} = p_I^{\text{half}}$. If we simulate the first year of an epidemic using our basic parameters (Table 2; also see parameter panel in Fig. 2) and adaptive contact half-max parameters for the cases $p_I^{\text{half}} = 0.01$ and 0.02 (i.e., 1% and 2% prevalence respectively), we obtain the percent of susceptibles (uninfected) and cumulative deaths by day 365 provided in Table 3.

For purposes of comparison, we also provide in Table 3 the percent of susceptible individuals and percent of deaths due to COVID-19 one year after the day

Table 2: Parameter values used to simulate single and multivariant outbreaks

Parameter	Symbol	Value	Source/Comment
single-variant simulations			
Time unit	t	daily	empirical data is daily
Nominal pop size	N_0	10^5-10^7	see Section 3.1[‡]
Effective contact rate[†]	κ_0	3 per day	implies $R_0 \approx 3.1^+$
Transmission	β	0.3	implies $R_0 \approx 3.1^+$
Latent Period	σ_{E}	4 days	median time in E[¶]
Infectious period	σ_{I}	7 days	median time in I[§]
Immunity half-life	t^{half}	1/2 to 1 year$^\pm$	per run specs.[‖]
Disease-induced mort.[**]	p_α	2% of cases*	mortality rate is $\alpha^{\#}$
Adaptive contact param.	$p_{\mathrm{I}}^{\mathrm{half}}$	0, 0.002, 0.05	decreasing $\kappa(I)^{*\dagger}$
Seasonal fluctuation param.	δ_{season}	0	seasons ignored^{*+}
Multi-variant simulations (single-variant parameter values used where applicable)			
Mutation factor*‡	μ	$0.001^{*\#}$	See Eq. A.13
variant number	$j = 0, ..., 2^{J-1}$	J is 0 to 7	i.e., 2 to 128 variants
Cross immunity	c_{mj}	0.8	Eqns. 1, 2
Pathogen shedding	$\bar{\zeta}_{j\ell}$	$0.001^{*\#}$	See Eq. A.9
Environmental persistence	$\bar{\eta}_j$	1 for all j	See Eq. A.10
Transmission	$\bar{\beta}_j$	$\delta_\beta \in [0, 0.2]$	See Eq. 4
Within-host replication rate	λ_j	1 for all j	See Eq. A.13
Disease-induced mort.[**]	p_{α_j}	0.02	See Eq. 5

[‡]In particular see discussion headed: *Population size and demographic stochasticity*

$^+$See Eq. A.26

[†]See Eq. A.7

[¶]Reciprocal of γ in continuous time computation of R_0 per Eq. A.26

[§]Reciprocal of ρ in continuous time computation of R_0 per Eq. A.26

$^\pm$Based on statement in [23]: "... studies of animal coronaviruses antibody titers ... waned substantially 1 year after initial infection ... and many could be reinfected and shed virus ..."

[‖]See Eq. A.6: note $w(t)$ switches from 1 to 0 as immunity goes from complete to absent

*Value at start of the pandemic, but typically lower later in most regional epidemics $^{\#}$This is "virulence" parameter of continuous-time SEIR models

[**]If $\alpha << 1$ then $p_{\alpha_j} = 1 - e^{-\alpha} \approx \alpha$

*†See Eq. A.7. Setting $p_{\mathrm{I}}^{\mathrm{half}} = 0$ implements $\kappa(0) = \kappa_0$, though $\kappa(t) \to \kappa_0$ as $p_{\mathrm{I}}^{\mathrm{half}} \to \infty$

$^{*+}$Implies values of k and θ in Eq. A.10 are irrelevant

*‡variant independent—variant dependence requires more elaborate model

$^{*\#}$Quantifies the mutation rate observed at a population rather than within-cell replication level

[**]If $\alpha_j << 1$ then $p_{\alpha_j} = 1 - e^{-\alpha_j} \approx \alpha_j$

347   on which more than 10 cases of COVID-19 were recorded to occur in the USA,
348   Italy and Czechia (extracted from data provide at Worldometer). Since these
349   data are known to be substantially under reported for both cumulative preva-

³⁵⁰ lence [40] and deaths [41], we felt that $p_{\mathrm{I}}^{\mathrm{half}} = 0.01$ (i.e. 1% prevalence) provides
³⁵¹ a reasonable ballpark value for an adaptive contact rate half-max parameter for
³⁵² our various illustrations provided in below.

Table 3: Basic runs with one million individuals ($N = 1,000,000$) using two different half-max adaptive contact parameter values $p_{\mathrm{I}}^{\mathrm{half}}$ compared with listed countries[*]

| | $p_{\mathrm{I}}^{\mathrm{half}}$ | | USA | Italy | Czechia |
	1%	2%	(values under reported)[‡]		
Uninfected at day 365	82%	71%	93%	95%	88%
COVID-19 deaths by day 365	0.34%	0.55%	0.12%	0.17%	0.21%

[*]Data from Worldometer

[†]One year after the first 10 recorded cases in the countries concerned

[‡]Substantial under reporting occurs for both cases [40] and deaths [41].

³⁵³ Population size and demographic stochasticity

³⁵⁴ Deterministic SIR/SEIR and related models will always produce an epidemic
³⁵⁵ whenever the parameters ensure that $R_0 > 1$ [2,34]. Since these models do not
³⁵⁶ include the demographic stochastic effects associated with finite populations,
³⁵⁷ they are unable to capture the phenomenon of stochastic extinction of the epi-
³⁵⁸ demic before it gets going when a single infected individual is introduced into
³⁵⁹ an otherwise infected population (with regard to the pathogen in question; see
³⁶⁰ discussion in SOF A.4). In such models, results are either cited using percent-
³⁶¹ ages or numbers per thousand or per hundred thousand individuals and the
³⁶² actual population size is not regarded as a factor. Population size, however, is
³⁶³ a factor in determining the absolute size of an epidemic once it gets started and
³⁶⁴ deterministic models provided a robust assessment of the course of the epidemic
³⁶⁵ in populations consisting of millions of individuals (other factors, such as spatial
³⁶⁶ or contact network structure play a more important role than size per se [5–7]).
³⁶⁷ To get a sense of the effects of demographic stochasticity on populations of
³⁶⁸ different sizes in our simulations, we compared the prevalence, incidence, and
³⁶⁹ cumulative deaths obtained for single runs (runtime seed = 1) of a basic adaptive
³⁷⁰ contact rate scenario (basic parameters plus $p_{\mathrm{I}}^{\mathrm{half}} = 0.01$) for cases where the
³⁷¹ initial population sizes where $N_0 = 10,000$, 100,000 and 1,000,000 (Fig. 3A-C).
³⁷² We also compared the mean prevalence plus/minus 1 standard deviation (sd) for
³⁷³ 100 runs (runtime seeds ranging from 0 to 99) for the two cases $N_0 = 10,000$ and
³⁷⁴ 100,000 over both the first year (Fig. 3D & E) and the first 100 day (Fig. 3F).
³⁷⁵ The results depicted in Fig. 3 can be encapsulated in the following four
³⁷⁶ well-established principles:

³⁷⁷ 1. The initial phase of an outbreak is independent of population size and
³⁷⁸   establishment of an epidemic depends solely on the value of R_0 (SOF,
³⁷⁹   Append A.4). Thus, as we see in Fig. 3F, the first 50 days of the mean
³⁸⁰   prevalence for the simulations of the cases $N = 10,000$ and $N = 100,000$

are virtually identical, only departing from one another from around day
50 onwards.

2. Beyond the initial phase, stochastic fluctuations are more evident in smaller
than larger populations (compare Figs. 3A, B and C)

3. Ultimate prevalence levels, aside from stochastic fluctuations are indepen-
dent of population size. Thus, for example, we see that prevalence maxes
out at round 0.6% in all three cases (dotted line) across a range of two
orders of magnitude in population size.

4. Mean population prevalence will always max out at lower levels than the
prevalence reached in actual runs (viz. the max exceeds 7% individual
runs in Fig. 3A-C while it is between 4% and 5% for the red curves in
Fig. 3D&E) because the mean values take into account the fact a propor-
tion $1/R_0$ of the runs go extinct within the first several weeks [42].

Figure 3: **A-C**: Plots of percentage prevalence (red), incidence (purple) and cumula-
tive dead (black) for 365 day simulations using the parameter values given in Table 1
with the adaptive contact rate parameter $p_{\mathrm{I}}^{\mathrm{half}} = 0.01$ (see Eq. A.7) and $N = 10,000$,
$N = 100,000$ and $N = 1,000,000$ respectively. **D-E**: Plots of mean percentage preva-
lence (red) over the first year plus (green) minus (blue) 1 standard deviation over 100
runs (runtime seeds going from 0 to 99) for the cases $N = 10,000$ and $N = 100,000$
respectively. **F**: Plots of the actual prevalence (number of individuals) for the first 100
days for the cases $N = 10,000$ (red) and $N = 100,000$ (black).

3.2   Multivariant simulations

We carried out a series of multivariant simulations with $J = 4$ (i.e., 16 variants
can emerge) in a population of size $N = 50,000$. We compared the scenarios of
cascading cross immunity with $c = 0.8$ (Eq. 1) and transmissions rates the same
for all variants (Fig. 4A) with the same cascading cross immunity as in Fig. 4A,

but now we allowed transmission to increase by 20% for each mutation difference
between variant j and variant 0 ((Eq. 1; $\beta_j = 0.3$, $j = 0, ..., 15$, $\delta_\beta = 0.2$ and
β_j, $j = 1, ..., 15$, determined using Eq. 4). Finally, we compared the scenario
of cascading cross immunity with that of escaping cross immunity for the case
$c = 0.8$ (Eq. 2), and obtained the results provide in Fig. 4C. The severity of
each scenario is encapsulated in the total death statistic over the course of the
two-year simulation.

Figure 4: Total daily incidence ($\Delta I+$: purple) and variant-specific prevalence (I: red) for a 16-variant epidemic in a population of size $N = 50,000$ (for other parameter values see Table 2) are plotted over a two-year period for the three cases: **A.** cascade cross immunity $\delta_\beta = 0.0$ (i.e., all $\beta_j = 0.3$, $j = 0, ..., 15$) and $\delta_\beta = 0.2$ (i.e., $\beta_0 = 0.3$, $\beta_{15} = 0.622$ and β_j, $j = 1, ..., 14$, determined using Eq. 4). Variant number and corresponding binary representation as labeled in red for dominant or co-dominant variants (incidence at some point > 50 individuals per day) and gray for minor variants (incidence always < 50 over the two-year simulation). The order of emergence of dominant or co-dominant variants is labeled in green. Note that each panel has its own vertical scale but all plots are over 730 days (even in cases where the horizontal axis label go to 750).

Our primary observations comparing the results plotted in Fig. 4A-C and other runs (not shown here) of the same scenarios using different runtime seeds, are the following:

- In all three cases the initial variant, by construction, is $0 \equiv (0,0,0,0)$. In our three scenarios, this variant was followed by chance by the emergence of variant $8 \equiv (1,0,0,0)$, but this is common to all three scenarios because they use the same sequence of pseudo random numbers in their simulations. Using different runtime seeds, however, leads to other variants than 8 emerging to replace variant 0. Thus, the mutant identity (i.e., its binary representation) of the variant to first emerge is somewhat random, but it is going to be influenced by having different transmission values for each variant (scenarios B and C), as well as the possibility of an idealized escape mutation (scenario C).

- We expect variants that have an idealized escape mutation to emerge early, as is the case in scenario C in which variants 8-15 have the idealized escape mutation. In particular, in Fig. 4C, we see that the second to fourth variants to emerge all have the idealized escape mutation (i.e., variant 8 then 14 and then 15), and finally variant $6 \equiv (0,1,1,0)$ emerges because of the cross-immunity between all variants with the idealized escape mutation finally comes into play.

- When $\delta > 0$, the variants with the higher values of β come to dominate, though they take time to emerge. In our cascading cross-immunity case with $\delta_\beta = 0.2$, the most transmissible of these (variant $15 \equiv (1,1,1,1)$) had yet to emerge within the simulated 2-year period. The existence of the idealized escape mutation, however, does facilitate the emergence of variant 15 at the beginning of the second year (Fig. 4C). Another run of this scenario (runtime seed=1; results not shown here) has variant 15 emerging very early (around day 120). Further, due to the effects of cross immunity, this variant was replaced by variant $11 \equiv (1,0,1,1)$ around days 450-500. Variant 15, however, as result of waning and cross-immunity affects, reemerges again around day 600, with variant 11 declining over the last three months of the second year.

3.3 Vaccination rollout

Single valency vaccinations

As illustrations of potential issues associated with the design and implementation of vaccination programs, we first considered vaccinating individuals in a population of 100,000 subject to an epidemic involving a single variant of the pathogen. We note that in a population of $N = 100,000$ individuals, a vaccination rate of $v(t) = 0.001$ involves vaccinating an average of 100 individuals per day with daily variation following a binomial distribution (i.e., a standard deviation of just under 10 individuals per day).

Rollout of our vaccination program began on day 366 after the start of the outbreak and ran for two years beyond that to day 1100 (Fig. 5). Such scenarios place us within the context of the COVID-19 epidemic since vaccinations were

only available from around the second year onwards. In our first two scenarios, we selected individuals respectively at rates 0.1% ($v = 0.001$) and 0.2% ($v = 0.002$) of the population each day (Fig. 5A & B). Only individuals that had not been previously vaccinated were selected, but selection was otherwise random.

Additionally, we simulated a 16-variant scenario in which individuals were vaccinated at against variant 0 at rate $v = 0.002$ (Fig. 5C). Again, individuals were selected at random from the set of those that had not been previously vaccinated. By vaccinating individuals against variant 0, some immunity was conferred against variants 1-7 through cross-immunity relationships according to the Escaping **C** case with cross-immunity parameter $c = 0.8$ (Eqn. 2). In this scenario, variants 8-15 contain the idealized escape mutation.

Our focal question with regard to the first two scenarios was: What vaccination level is needed to extinguish the epidemic in the population encompassed by the vaccination rollouts for the populations concerned? From these two simulations (Fig. 5A & B) we see that vaccination rate $v(t) = 0.001$ was insufficient to eliminate the pathogen from the population, while $v(t) = 0.002$ was able to eliminate the pathogen within 10 months from the start of the vaccination rollout. Further, in the first of these simulations (Fig. 5A), we see a resurgence of incidence in year three, which implies that the effects of waning immunity in this case are essentially "outrunning the vaccination rate."

Our focal question with regard to a comparison of scenarios two and three (Fig. 5B & C) was: Does the vaccination rate $v(t) = 0.002$, which was able to exterminating the outbreak in the 1-variant case, remain able to exterminate the outbreak in the 16-variant case when an idealized escape mutation is involved? The answer to this question from the observed incidence curve (Fig. 5C) is a resounding no. In fact, the total death rate over the three year period rose from 0.13% of the population (1336 individuals) to 0.42% of the population (4,235 individuals).

Adaptive bivalent vaccinations

With the emergence of new variants, the possibility exists to modify vaccines to contain or induce the production of antigens that directly target the variant in question (i.e., rather than through cross-immunity that arises when a related variant is the direct target) [28]. Further, it is possible for vaccines to be multivalent in terms of directly targeting more than one variant at time [28]. In our third vaccination scenario, a univalent vaccine applied at a rate $v = 0.002$ failed to bring a multivariant epidemic under control. Thus we were motivated to explore a scenario to see what would happen with a bivalent vaccine that was implemented adaptively in the sense of its two valencies following the two dominant variants.

In the specific vaccination rollout program that we employed in our fourth simulation, we did not account for logistical, production, and variant monitoring constraints. Such constraints, of course, exist and vary across locations and populations: in real applications, they need to be taken into account. The program we employed assumes that we are able to alter the valency of the vaccination used every 15 days, based on an ability to identify the two variants that are most prevalent at each of these successive 15-day-apart observation

Figure 5: Incidence (ΔI^+: purple) is plotted over 3 years for the baseline run (parameters given in Table 1 with $N = 100,000$) for the cases where vaccination rates $v(t)$ (indicated by blue lines) are applied during the second and third years only to individuals not previously vaccinated but otherwise selected at random (for clarification, the average number of individuals vaccinated each day is $100v(t)\%$ with variation following a binomial distribution). Our first two simulations involve vaccination rollout programs in a single variant epidemic at vaccination rates **A.** $v(t) = 0.001$ and **B.** $v(t) = 0.002$ (respectively 0.1% and 0.2%) of individuals not previously vaccinated, but otherwise chosen at random. Our second two simulations involve vaccination rollout programs in a 16-variant epidemic, both at vaccination rates $v(t) = 0.002$, involving **C.** individuals not previously vaccinated and **D.** a bivalent adaptive vaccination program in which previously vaccinated individuals could be vaccinated again with a new valency vaccine, as described in the text.

⁴⁹⁶ points (from day 365 to day 1085, which is the start of the last 15 day period
⁴⁹⁷ ending just prior to the start of day 1100). If only one variant had an incidence
⁴⁹⁸ exceeding 9 individuals on an observation day, then the vaccination applied over
⁴⁹⁹ the next 15 day interval was monovalent for the dominant variant, otherwise
⁵⁰⁰ it was bivalent for the two variants that had the highest incidence on that
⁵⁰¹ observation day.

⁵⁰² As with the non-adaptive vaccination rollouts, individuals were selected at
⁵⁰³ random from a pool that had previously not been vaccinated with the partic-
⁵⁰⁴ ular valency-specific vaccine (either bivalent or monovalent). However, in the
⁵⁰⁵ bivalent vaccine case, if an individual had previously been vaccinated to only
⁵⁰⁶ one of the two variants defining the latest vaccine, then these individuals were
⁵⁰⁷ incorporated into the vaccination pool from which individuals were randomly
⁵⁰⁸ selected for vaccination. If such individuals were selected then the start of the
⁵⁰⁹ waning time relating to the previous vaccination was reset to start anew. Thus,
⁵¹⁰ with this program, it is possible for individuals to be vaccinated more than once.

⁵¹¹ The results of this simulation are depicted in Fig. 5D, where we see that
⁵¹² this vaccination program is much more effective in preventing deaths than the

monovalent variant 0 program applied to the same 16-variant epidemic at the
same vaccination rate Fig. 5C (total deaths are 4,235 in the former versus 2145
in the latter case). The valencies of the vaccine applied during each new 15
day period are listed in Table 4. We note that the monovalent case involves
considerably fewer vaccinations because of the "no revaccination with the same
vaccine" restriction in our rollout program. In particular, over two years of
vaccinating at a 0.2% rate per day, all individual are vaccinated in the case of
Fig. 5C by day 859 while, in the case of Fig. 5, revaccinations kept occurring
as individual that have not previously been vaccinated to one of the focal vari-
ants was revaccinated. Even in this adaptive rollout, however, the epidemic was
only substantially lowered rather than completely extinguish. The latter event
for the set of parameters used in our simulation requires a somewhat higher
vaccination rate than 0.2% per day; or, perhaps it requires lower rates of wan-
ing immunity, higher cross-immunity rates, or the lack of an idealized escape
mutation. All of these effects can be demonstrated through the selection of ap-
propriate parameter values, but the specifics are only relevant when the model
is applied in a real world situation.

Table 4: Valency of adaptive vaccination over the interval $[365, 1100]$

Time	Valency
$[365, 470)$	(9,14)
$[470, 530)$	(13,14)
$[530, 680)$	(13,15)
$[680, 740)$	(15)
$[740, 905)$	(10,15)
$[905, 1025)$	(10,12)
$[1025, 1070)$	(12,15)
$[1070, 1100)$	(15)

4   Discussion

The amount of structure and data needed in complex biological systems' mod-
els, depends on the questions that these models have been formulated to ad-
dress [13,14]. In this paper, we steered away from making specific predictions—
because universal solutions are not always locally applicable. Rather, we focused
on gaining insights into incidence patterns that can be expected when contacts
are adaptive rather than fixed, multiple variants may emerge (typically sequen-
tially over time), and open versus adaptive uni- and multivalent vaccination
programs are implemented to try to eliminate local pandemics. Analyses that
incorporate more complexity in the hopes of attaining greater realism, such as
adding heterogeneity related to age and spatial structures, as well as behavioral
and social groups, require data that is specific to a local population (town, city,
county, or small country, etc.) Such elaborations are only worth incorporating
when the study relates to a real world system supported by adequate data (the

latter related to the complexity of the question that needs to be addressed, as
discussed elsewhere [13]).

Of course, additional structure can be added to address questions of general
interest. One obvious issue relating to our study would be to obtain a better
understanding of the role informational delays may play in producing the type of
incidence waves that have observed over the course of the COVID-19 pandemic
(and as we have modeled in [43]). Such delays would lead to contact rates
containing a time-lag rather than depending only on current prevalence levels.
We might also spend more time deconstructing the relative importance of such
time delays versus the emergence of more transmissible variants in accounting
for these waves.

Beyond gaining a deeper understanding of some of the mechanisms responsi-
ble for the incidence patterns observed among local epidemics of the COVID-19
pandemic, a second and primary purpose of our paper is to present our M-
SEIR RAMP as a platform that others may use to address issues of concern
to them in formulating policies to manage local COVID-19 epidemics. This
also has the advantage of providing an exemplar of our novel RAMP (runtime
alterable model platform) concept and the methods we used to construct it.
At this time, the primary value of our M-SEIR RAMP itself may be in testing
various vaccination strategies as they relate to variant emergence [44]. Clearly,
such applications would require more specific variant-related information on
the comparative transmissibility β_j, virulence α_j, shedding ($\bar{\zeta}_{jm}$), environmen-
tal persistence ($\bar{\eta}_j$), and within host replication rates (λ_j) of newly emerging
variants.

Equally important, though, in evaluating the impacts of vaccination strate-
gies on local epidemics is obtaining variant-specific immunity and cross-immunity
data. This includes waning rates, which we have not made variant specific. Our
model, however, could be generalized to include variant specific waning rates
represented by the parameter t_j^{half} (Eq. A.6). It also includes information for
characterization of the elements $c_{j\ell}$ of the cross immunity matrix $\mathbf{C}$ (i.e., a
generalization that renders Eq. 1redundant). Models are sorely needed to ex-
plore multivariant dynamics, particularly the epidemiological properties regard-
ing shedding, environmental persistence, transmission, mutation, and within-
host replication rates. These processes, acting together, determine the relative
success of different variants and their actual impact on the severity of epidemics
and the nature of vaccination programs needed to suppress them.

Making our model both location and variant specific could be undertaken
using methods, such as Appropriate Complexity Modeling [13, 14], designed to
enhance the relevancy of models. Further, in some cases it may be useful to
add spatial or age-structure information to our M-SEIR or include a contact
network [7], which itself may contain spatial or refined class category (e.g. age
or work categories) information. In addition, our current implementation repre-
sents variant differences in terms of J loci with two alleles (denoted by 0 and 1
respectively) at each locus. A more realistic representation of the genetic basis
of variant differences may involve genetic representations in which several alleles
are possible at each locus. Further, the loci themselves may represent relevant
molecular structures such as epitopes.

An advantage of our RAMP design features is that they provide a framework

for elaborating or simplifying model details in the pursuit of different questions at various points in a pandemic. For example, suppose we are interested in pursuing inferences regarding the drivers of variant evolution at a various stages of the pandemic. We may first want to address questions relating to pandemic behaviour, driven by mutations that increase transmissibility. This is what actually happened with the appearance of the D614G and the alpha variants. A year or so into the pandemic, however, we may then want to explore processes that give rise to immunity-escaping variants. This, again, is what happened in reality. Our RAMP formulation gives us the flexibility to change the model part way through a pandemic. In particular, we can then test which among a set of alternative reinfection process is most likely to produce an escape mutation once reinfection begins to occur on a substantial scale. By configuring model drivers so that we first have a relatively simple evolutionary process and then switch to more complex evolutionary processes, our RAMP design facilitates comparing several competing explanations of observed patterns of variant emergence at different stages of a pandemic.

Although cross-immunity and immune waning are entangled in our immunity modifier functions (i.e., ϕ_{ij} ; see Eq. A.8), cross-neutralization data can be used to estimate the cross and waning immunity parameters using appropriate methods [45]. Such data are becoming more widely available through the application of improved serological and genetic methods [24, 46, 47]. Variant and cross neutralizing studies bring up a much neglected issue, which is the effect of dose (number of pathogens involved in the initial infection, also know as viral load) on the severity of the infection. Further, dose affects both the probability of host invasion (in the context of transmission), as well as mutational rates once host invasion has occurred. Effective dose differs from the questions of the number of vaccine doses (typically one versus two) versus the antigen or virus-like particle load in each dose [48]. In the context of vaccination, both these issues and the technology used to produce the vaccine [28] may well have an impact on waning immunity rates and cross-immunity values. Thus, the parameter values used in the model should ultimately be vaccine specific, once vaccine-specific waning data have been obtained.

In the coming years, as we obtain more information on the nature of waning and cross immunity to different variants of SARS-CoV-2, not to mention the vaccines as well, it will become more apparent to us whether or not COVID-19 will settle into global endemicity [32, 49] and require periodic vaccinations to combat new variants, as they arise over time. If this is the case, then constant vigilance and a well-designed vaccination program with respect to vaccinating the young and implementing booster vaccinations with appropriate variant valency will become the order of the day. Additionally, we anticipate extending our M-SEIR RAMP to include runtime alterable modules (RAMs) designed to compute the optimal time to administer vaccine booster shots of the same or different variant valencies. Implementation of these RAMs can play a decisive role in the rational design of effective and efficient COVID-19 vaccination programs worldwide. The need for efficacy is made apparent from the fact that our simulations suggest that it may be harder than currently anticipated to eliminate COVID-19 using non-adaptive vaccination programs.

Finally, our M-SEIR RAMP, with its RAMs, driver scripts and ability to

be integrated with R and other software platforms and a JavaScript simulation
driver window, provides the first example of a new concept in model implemen-
tation that facilitates model sharing and easy modification by users other than
the original developers. We believe such platforms can come to play an impor-
tant role not only in disease modeling, but in all fields of research that rely on
models for comprehensive analyses of the behavior of systems of interest.

Acknowledgements and Funding Sources

647 This work was funded in part by NSF Grant 2032264 (PI: WMG).

References

[1] Kermack WO, McKendrick AG. A contribution to the mathematical theory of epidemics. Proceedings of the royal society of london Series A, Containing papers of a mathematical and physical character. 1927;115(772):700–721.

[2] Hethcote HW. The mathematics of infectious diseases. SIAM Review. 2000;42(4):599–653.

[3] Koelle K, Cobey S, Grenfell B, Pascual M. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science. 2006;314(5807):1898–1903.

[4] Gilchrist MA, Sasaki A. Modeling host–parasite coevolution: a nested approach based on mechanistic models. Journal of Theoretical Biology. 2002;218(3):289–308.

[5] Balcan D, Gonçalves B, Hu H, Ramasco JJ, Colizza V, Vespignani A. Modeling the spatial spread of infectious diseases: The GLobal Epidemic and Mobility computational model. Journal of computational science. 2010;1(3):132–145.

[6] Keeling MJ. The effects of local spatial structure on epidemiological invasions. Proceedings of the Royal Society of London B: Biological Sciences. 1999;266(1421):859–867.

[7] Keeling MJ, Eames KT. Networks and epidemic models. Journal of the Royal Society Interface. 2005;2(4):295–307.

[8] Bauer AL, Beauchemin CA, Perelson AS. Agent-based modeling of host–pathogen systems: The successes and challenges. Information sciences. 2009;179(10):1379–1389.

[9] Cuevas E. An agent-based model to evaluate the COVID-19 transmission risks in facilities. Computers in biology and medicine. 2020;121:103827.

[10] Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature microbiology. 2020;5(11):1403–1407.

[11] Koopman JS, Simon CP, Getz WM, Salter R. Modeling the population effects of escape mutations in SARS-CoV-2 to guide vaccination strategies. Epidemics. 2021;p. 100484.

[12] Aslaner H, Aslaner HA, Gökçek MB, Benli AR, Yıldız O. The effect of chronic diseases, age and gender on morbidity and mortality of covid-19 infection. Iranian Journal of Public Health. 2021;50(4):721.

[13] Getz WM, Salter R, Mgbara W. Adequacy of SEIR models when epidemics have spatial structure: Ebola in Sierra Leone. Philosophical Transactions of the Royal Society B. 2019;374(1775):20180282.

[14] Larsen LG, Eppinga MB, Passalacqua P, Getz WM, Rose KA, Liang M. Appropriate complexity landscape modeling. Earth-science reviews. 2016;160:111–130.

[15] Getz WM, Salter R, Luisa Vissat L, Horvitz N. A versatile web app for identifying the drivers of COVID-19 epidemics. Journal of Translational Medicine. 2021;19(1):1–20.

[16] Rahimi I, Chen F, Gandomi AH. A review on COVID-19 forecasting models. Neural Computing and Applications. 2021;p. 1–11.

[17] Chretien JP, George D, Shaman J, Chitale RA, McKenzie FE. Influenza forecasting in human populations: a scoping review. PloS one. 2014;9(4):e94130.

[18] Getz WM, Gonzalez JP, Salter R, Bangura J, Carlson C, Coomber M, et al. Tactics and strategies for managing Ebola outbreaks and the salience of immunization. Computational and mathematical methods in medicine. 2015;2015.

[19] Chen PZ, Bobrovitz N, Premji Z, Koopmans M, Fisman DN, Gu FX. Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols. eLife. 2021 apr;10:e65774. Available from: https://doi.org/10.7554/eLife.65774.

[20] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. New England Journal of Medicine. 2020;382(16):1564–1567. Available from: https://doi.org/10.1056/NEJMc2004973.

[21] Maginnis MS. Virus–receptor interactions: the key to cellular invasion. Journal of molecular biology. 2018;430(17):2590–2611.

[22] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. bmj. 2021;372.

[23] Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. 2020;.

[24] Eguia RT, Crawford KH, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger AL, Englund JA, et al. A human coronavirus evolves antigenically to escape antibody immunity. PLoS pathogens. 2021;17(4):e1009453.

[25] Alizon S, Luciani F, Regoes RR. Epidemiological and clinical consequences of within-host evolution. Trends in microbiology. 2011;19(1):24–32.

[26] Fenichel EP, Castillo-Chavez C, Ceddia MG, Chowell G, Parra PAG, Hickling GJ, et al. Adaptive human behavior in epidemiological models. Proceedings of the National Academy of Sciences. 2011;108(15):6306–6311.

[27] Gozzi N, Bajardi P, Perra N. The importance of non-pharmaceutical interventions during the COVID-19 vaccine rollout. medRxiv. 2021;Available from: https://www.medrxiv.org/content/early/2021/01/09/2021.01.09.21249480.

[28] Kumar A, Dowling WE, Román RG, Chaudhari A, Gurry C, Le TT, et al. Status Report on COVID-19 Vaccines Development. Current Infectious Disease Reports. 2021;23(6):1–12.

[29] Jefferies JM, Clarke SC, Webb JS, Kraaijeveld AR. Risk of red queen dynamics in pneumococcal vaccine strategy. Trends in microbiology. 2011;19(8):377–381.

[30] Willem L, Verelst F, Bilcke J, Hens N, Beutels P. Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015). BMC infectious diseases. 2017;17(1):612.

[31] Chowell G, Sattenspiel L, Bansal S, Viboud C. Mathematical models to characterize early epidemic growth: A review. Physics of life reviews. 2016;18:66–97.

[32] Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science. 2021;371(6530):741–745.

[33] Koyama T, Weeraratne D, Snowdon JL, Parida L. Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens. 2020;9(5):324.

[34] Getz WM, Lloyd-Smith JO. Basic methods for modeling the invasion and spread of contagious diseases. DIMACS Series in Discrete Mathematics and Theoretical Computer Science. 2006;71:87.

[35] McCallum H, Barlow N, Hone J. How should pathogen transmission be modelled? Trends in ecology & evolution. 2001;16(6):295–300.

[36] Anderson RM, May RM, et al. Coevolution of hosts and parasites. Parasitology. 1982;85(Pt 2):411–426.

[37] Getz WM, Salter R, Muellerklein O, Yoon HS, Tallam K. Modeling epidemics: A primer and Numerus Model Builder implementation. Epidemics. 2018;25:9–19.

[38] Getz WM, Salter R, Lyons AJ, Sippl-Swezey N. Panmictic and clonal evolution on a single patchy resource produces polymorphic foraging guilds. PloS one. 2015;10(8):e0133732.

[39] Hussein M, Toraih E, Elshazli R, Fawzy M, Houghton A, Tatum D, et al. Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2. Annals of surgery. 2021;273(3):416–423.

[40] Lau H, Khosrawipour T, Kocbach P, Ichii H, Bania J, Khosrawipour V. Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters. Pulmonology. 2021;27(2):110–115.

[41] Karlinsky A, Kobak D. Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. eLife. 2021;10:e69336.

[42] Hartfield M, Alizon S. Introducing the outbreak threshold in epidemiology. PLoS pathogens. 2013;9(6):e1003277.

[43] Getz WM, Luisa Vissat L, Salter R. A Contact-Explicit Covid-19 Epidemic and Response Assessment Model. medRxiv. 2020;.

[44] Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell host & microbe. 2021;29(1):44–57.

[45] Funk S, King AA. Choices and trade-offs in inference with infectious disease models. Epidemics. 2020;30:100383.

[46] Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Reports Medicine. 2020;1(3):100040.

[47] Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nature communications. 2020;11(1):1–6.

[48] Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology. 2020;20(10):615–632.

[49] Tkachenko AV, Maslov S, Elbanna A, Wong GN, Weiner ZJ, Goldenfeld N. Time-dependent heterogeneity leads to transient suppression of the COVID-19 epidemic, not herd immunity. Proceedings of the National Academy of Sciences. 2021;118(17).

[50] Anderson RM. The impact of vaccination on the epidemiology of infectious diseases. In: The Vaccine Book. Elsevier; 2016. p. 3–31.

[51] Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC infectious diseases. 2006;6(1):1–8.

[52] Liu X, Huang J, Li C, Zhao Y, Wang D, Huang Z, et al. The role of seasonality in the spread of COVID-19 pandemic. Environmental research. 2021;195:110874.

[53] Valtonen A, Molleman F, Chapman CA, Carey JR, Ayres MP, Roininen
     H. Tropical phenology: Bi-annual rhythms and interannual variation in an
     Afrotropical butterfly assemblage. Ecosphere. 2013;4(3):1–28.

[54] Lythgoe KA, Hall M, Ferretti L, de Cesare M, MacIntyre-Cockett G,
     Trebes A, et al. SARS-CoV-2 within-host diversity and transmission.
     Science. 2021;372(6539). Available from: https://science.sciencemag.
     org/content/372/6539/eabg0821.

APPENDICES

A   Model Construction

Here we formulate an individual-based or agent-based (ABM) SEIR epidemiological model to include host immunological waning and pathogen genetic drift with variation across variant transmissibility and virulence and succintly refer to it as an elaborated SIR (M-SEIR) model. [50]

A.1   Assumptions, definitions, and states

The population consists of a well-mixed pool of N_0 individuals that is homogeneous except for the fact that some are uninfected (denoted S), some currently infected (E: exposed and not yet infectious; I infectious and asymptomatic or symptomatic) or have been infected and are now either dead (D) or recovered/vaccinated with some level of immunity (V) to one or more of 2^J pathogen variants. This immunity wanes over time and its current level, augmented by specified levels of variant cross-immunity, factored into an agent specific time-dependent variant-resistance function that impacts the shedding of mutant variants by infectors and the within-host replication rates of mutant variants in infectees.

At the start of the epidemic, all individuals are assumed to encounter, on average, $\kappa_0 > 0$ other individuals during each time period $[t, t+1]$, but this "effective contacts" rate adaptively decreases with increasing prevalence of the disease due to the implementation of non-pharmaceutical interventions (social distancing, hand washing, mask wearing, and other hygienic precautions). In our selection of epidemiological parameter values, a unit of time is taken to be a 24-hour day. Other scalings of time would then require appropriately adjusted epidemiological parameter values. Refined versions of the model could include age-related parameter values and contact rates, as well as contact tracing, quarantining, and isolation of infected individuals; but these will not be considered here.

Initially, at model time $t = 0$, all individuals are considered SARS-CoV-2 naïve susceptible apart from one individual who is considered to have just entered the infectious stage, infected by a pathogen designated as pathogen variant 0 (wildtype). Throughout the model simulation, the N_0 agents in the population are partitioned into three disjoint sets: the set of SARS-CoV-2 naïve individuals, $\mathbf{S}(t)$, containing $N_S(t)$ (the susceptibles); the set of identified agents, $\mathbf{A}(t)$, containing $N_A(t)$ individuals who are either currently infected (time t) with a particular variant of SARS-CoV-2, or have some level of waning immunity to one or more variants of SARS-CoV-2; and the set of dead individuals $\mathbf{D}(t)$, currently of size $N_D(t)$. Only the individuals in $\mathbf{A}(t)$ are uniquely identified as they become infected for the first time and make the transition from set $\mathbf{S}(t)$ to set $\mathbf{A}(t)$, where they are sequentially labeled using the index $i = 1, ..., N_A(t)$. The single infected individual at time zero will be designated Agent 1 (also known as patient zero and denoted by A_1). Thus at time t it follows that

$$N_S(t) + N_A(t) + N_D(t) = N_0 \quad \text{(a constant)} \tag{A.1}$$

⁴³   We note that individuals in set $\mathbf{A}(t)$ can be in a disease state E or I with
⁴⁴ respect to pathogen j, but simultaneously can be in multiple immune states if
⁴⁵ they have been infected with more than one pathogen variant in the past. We
⁴⁶ also note that the distinction between symptomatic and asymptomatic individ-
⁴⁷ uals in state I will not be considered here; and only need be incorporated if
⁴⁸ testing, quarantining, and treatment processes are included in the model.
⁴⁹   The total number of pathogen variants is set by a parameter $J > 0$, where
⁵⁰ each pathogen is represented by a J-bit binary number. Thus, there are 2^J
⁵¹ possible variants indexed by $j = 0, 1, 2, \ldots, 2^J - 1$ where j is the decimal equiv-
⁵² alent that corresponds to a given binary string. The initial variant, $j = 0$ is the
⁵³ binary string of J zeros.
⁵⁴   Sets of stochastic epidemic events (i.e., transitions from classes S to E, E to
⁵⁵ I, I to V or D) are implemented at consecutive integer points in time (one set
⁵⁶ of events for each point in time). Events will only be considered on individuals
⁵⁷ that have been infected by at least one of the pathogens at some time after $t = 0$
⁵⁸ (this means that initially the epidemic computation proceeds rather rapidly, but
⁵⁹ becomes more computationally intensive for each time step as time proceeds).

⁶⁰ A.1.1   Pathogen set

⁶¹ At the start of the simulation ($t = 0$), the set of potential pathogens indexed by
⁶² $j = 0, ..., 2^J - 1$ is generated along with its associated environmental persistence
⁶³ ($\bar{\eta}_j$), transmission ($\bar{\beta}_j$), within host replication (λ_j) and disease-induced mortal-
⁶⁴ ity rate (probability of dying from the disease p_{α_j}) parameters. These may be
⁶⁵ specified or drawn from underlying distributions (e.g., the uniform distributions
⁶⁶ $\beta \sim \mathtt{Uniform}[\beta_{\min}, \beta_{\max}]$ and so on). Also, our model includes two $2^J \times 2^J$
⁶⁷ matrices of constants that are associated with pathogen mutations during vari-
⁶⁸ ant shedding (elements ζ_{jm}) and cross-immunity (elements c_{mj}) processes and
⁶⁹ thus involve but are conditioned on either the major variant that an infector
⁷⁰ is harboring or on immunological state of the agents involved. These are the
⁷¹ shedding and cross-immunity matrices with elements $j, m = 0, ..., 2^J - 1$, Thus
⁷² we generate the following list of parameters associated with our 2^J pathogen
⁷³ variants:

$$\text{Pathogen list} \quad = \quad \qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad\qquad \text{(A.2)}$$
$$\left\{ \left(\bar{\eta}_j, \bar{\beta}_j, \lambda_j, p_{\alpha_j}; \ \zeta_{jm} \text{ and } c_{mj} \text{ for } m = 0, ..., 2^J - 1 \right) \big| \ j = 0, ..., 2^J - 1 \right\}$$

⁷⁴ A.1.2   Agent states

⁷⁵ In accordance with the above set of assumptions, each agent has the following
⁷⁶ basic disease states at time t, where disease states in agent A_i are referenced by
⁷⁷ the time $\tau_j > 0$ at which the most recent infection with variant j has occurred
⁷⁸ (an individual may be re-infected after immunity to the variant has waned to
⁷⁹ relatively low levels):

⁸⁰   1. S(t): An individual who at time t has not been infected with any variant
⁸¹   of the pathogen up to time t. All these individuals belong to set $\mathbf{S}(t)$

2. $E_j(t, \tau_{ij})$: An agent A_i who was infected with variant j at time τ_{ij}, but
has not yet become infectious (this is an individual in the latent stage that
lasts for σ_E units of time). All these individuals belong to set $\mathbf{A}(t)$

3. $I_j(t, \tau_{ij})$: An agent A_i who is currently infectious with variant j, after
being infected with variant j at time τ_{ij} (this is the infectious stage that
lasts for σ_I units of time). All these individuals belong to set $\mathbf{I}(t) \subseteq \mathbf{A}(t)$

4. $V_j(t, \tau_{ij})$: An agent A_i who was infectious with variant j, having been
infected with variant j at time τ_{ij}, but is now non-infectious with regard
to this variant—that is, recovered with some immunity to variant j, as
well as some cross immunity to variants closely related to j. All these
individuals belong to set $\mathbf{A}(t)$

5. $D(t)$: An individual at time t who has died after being exposed to and
become infectious with some variant of the pathogen. In a refined version
of the model, a record will be kept of the time of death and the variant
that caused death. All these individuals belong to set $\mathbf{D}(t)$.

Since an agent A_i may be infected over time by more than one variant j, its
complete epidemiological state is represented by a list

$$A_i(t) = \{\text{state w.r.t. pathogen } 0, \cdots, \text{state w.r.t. pathogen } 2^J - 1\} \quad (A.3)$$

If a living agent does not fall into any of the categories 2 – 4 with respect to
pathogen j, we denote its epidemiological state at position j as $\emptyset$ (the empty
set). Consequently, if an agent A is susceptible at time t (i.e., an element of
$S(t)$), then we write
$$A_0(t) = \{\emptyset, \ldots, \emptyset\} \in \mathbf{S}$$

99   However, while such individuals are omitted from the A list (hence we did not
100   subscript the agent A above), they may be recognized as "virtual members"
101   with this implicit state. Some other examples are:

• If $A_i(t)$ is infected, but not yet infectious, with pathogen variant j at time
   t but has not been infected with any other pathogen in its past history,
   then
$$A_i(t) = \{\emptyset, \cdots, \emptyset, E_j(t, \tau_j), \emptyset, \cdots, \emptyset\}$$

• On the other hand if A_i recovered from an infection with pathogen 0 at
   time τ_0, and is now infectious with pathogen j at time t, having become
   infected with this pathogen at time τ_j then we write

$$A_i(t) = \{V_0(t, \tau_0), \emptyset, \cdots, \emptyset, I_j(t, \tau_j), \emptyset, \cdots, \emptyset\}$$

102   As we shall see, an agent history may contain at most one instance of either E_j
103   or I_j, while possibly containing multiple instances of V_j.

A.1.3   Agent and index sets

At the start of each time period, we update the set of identified agents $\mathbf{A}$ by adding susceptibles that became infected with pathogens during the previous time period and removing agents that died during the previous time period. Thus if $\mathbb{I}_A$ is the index set for non-empty elements of $\mathbf{A}$, with new indices added for newly infected susceptibles and indices removed for individuals that died, then by definition:

$$\mathbf{A}(t+1) = \{\mathrm{A}_i(t+1) | i \in \mathbb{I}_A(t+1)\} \tag{A.4}$$

where the number of indices in the updated set $\mathbb{I}_A(t+1)$ is $N_A(t+1)$ and the updated number of dead is $N_D(t+1)$ at time $t+1$.

For mathematical convenience all susceptibles S will also be referred to as A_0:, i.e., there are $N_S(t)$ individuals referenced by A_0 at time t. It will be useful to partition the set $\mathbf{A}(t)$ itself into three subsets at time t by identifying the sets $\mathbf{E}(t)$ and $\mathbf{I}(t)$ which respectively contain all agents that are currently in a state $\mathrm{E}_j(t)$ or a state $\mathrm{I}_j(t)$ at time t for some $j = 0, ..., 2^J - 1$. We note the intersection of these two sets is empty—i.e., $\mathbf{E}(t) \cap \mathbf{I}(t) = \emptyset$—as will become apparent below from the transmission process rules set up below. We will use the notation

$$\mathbf{A}_S(t) = \mathbf{A}(t) \setminus \big(\mathbf{E}(t) \cup \mathbf{I}(t)\big) \tag{A.5}$$

to denote the set of agents in $\mathbf{A}(t)$ but not in $\mathbf{E}(t)$ or $\mathbf{I}(t)$.

We also identify the set of infectious agents with infectious variant j. If A^j denotes an agent whose epidemiological state contains an entry $\mathrm{I}_j(t, \_)$, then

$$\mathbf{I}_j(t) = \{\mathrm{A}^j_{i_{1}}(t), \mathrm{A}^j_{i_{2}}(t), \ldots, \mathrm{A}^j_{i_{N_{\mathrm{I}_j}}}(t)\},$$

where the number of such agents is denoted by $N_{\mathrm{I}_j}(t)$, and its index set by

$$\mathbb{I}_{\mathrm{I}_j}(t) = \{i_{1_j}, \ldots, i_{N_{\mathrm{I}_j}(t)}\}.$$

A.2   Epidemiological processes

A.2.1   Immunity

In compartmental SIRS and SEIRS models, a concept of waning immunity and its impact on epidemics is associated with the rates at which individuals in class R revert back to class S. In agent-based SIRS and SEIRS models, we have the opportunity to consider the immunological history of individuals and, hence, can take a more refined approach to the complex process of how pathogens in an infector A_i are passed on the an infectee A_h. Here we model this as a probability generated from a concatenation of rates that include pathogen shedding by A_i, the survival of pathogens in the environment, whether contained in feces, urine, sweat, mucosal secretions or water droplets excreted by an infector, and a process whereby pathogens gain access to a host (entering through wounds, mucosal membranes or other membranes in the pulmonary or alimentary systems). We then characterize pathogen within-host variant replication rates in terms of pathogen mutational and reproductive processes. The final outcome

in our model is either host recovery with some immunity or host death. We also consider the induction of host immunity through vaccination and make the assumption that waning immunity is the same, whether it stems from natural infection or vaccination. Of course, these may be modelled in different ways should data become available to make this distinction an important modeling consideration.

Waning immunity. Recall that we use A_0 to denote an anonymous (generic) member of $\mathbf{S}$ and that A_i for $i > 0$ refers to a specific individual with an associated state list/vector. If some specific A_i is in immune state V_j having been infected with this variant at time τ_{ij}, we assume that the level of relative susceptibility of agent A_i to reinfection by variant j is given by (noting that the existence of the value τ_{ij} implies that infection of individual i by variant j at time τ_{ij} ensures that the V_j is no longer "null")

$$\omega_{ij}(t, \tau_{ij}) = \begin{cases} 0 & \text{if } V_j \text{ is null} \\ \dfrac{1}{1 + \left((t - \tau_{ij} - \sigma_\mathrm{I} - \sigma_\mathrm{E})/t_j^{\mathrm{half}}\right)^{\sigma}} & \text{if } t \geq \tau_{ij} + \sigma_\mathrm{I} + \sigma_\mathrm{E} \\ 1 & \text{if } t < \tau_{ij} + \sigma_\mathrm{I} + \sigma_\mathrm{E} \end{cases} \quad (\text{A.6})$$

We note the following: 1.) the first case implies that τ_{ij} has yet to be defined; 2.) the second case is equivalent to the statement that $\tau_{ij} \geq 0$ now exists for variant j, since this occurs at time $t = \tau_{ij}$ (through the invocation of state $E_j(t, \tau_{ij})$); 3.) $\omega_{ij}(t, \tau)$ ranges from 1 (i.e. full "on") at $t = \tau + \sigma_\mathrm{I} + \sigma_\mathrm{E}$ and decays to 0 as $t > \tau + \sigma_\mathrm{I} + \sigma_\mathrm{E} \to \infty$; 4.) agent i cannot be reinfected with its current major variant or with any other variant while it is currently itself in any state E_j or I_j for any $j = 0, ..., 2^J - 1$; 5.) the larger the value of σ the steeper or more abrupt the switch is from full immunity (equal to 1) at time τ through $1/2$ at time t_j^{half} to approach 0 as $t \to \infty$ (we set $\sigma = 4$ as providing an intermediate level of abruptness).

Vaccination. A vaccine may be designed to give immunity to one or more particular identified variant j. Vaccination strategies include vaccinating at a fixed rate $v(t)$ (percent of individuals vaccinated at each time period) over a fixed period that begins at t_v^{on} and ends at t_v^{off} and can focus on drawing only on: i) individuals in the set $\mathbf{S}$, ii) any non-infectious individual in $\mathbf{S}$ or $\mathbf{A}$, or iii) any non-infectious, not previously vaccinated individual in $\mathbf{S}$ or $\mathbf{A}$. The vaccine itself can be designed as follows:

- *Dominant variant vaccination at time τ_{vac}.* An individual S or A_i vaccinated with the dominant variant, say j, at time $\tau_{\mathrm{vac}} \in [t_v^{\mathrm{on}}, t_v^{\mathrm{off}}]$ serves to add the disease state $V_j(t, \tau_{\mathrm{vac}})$ to that individual's list. If the individual is already in state $V_j(t, \tau')$ at time $t > \tau_{\mathrm{vac}}$, then its status is updated so that at time $t > \tau_{\mathrm{vac}}$ it is now $V_j(t, \tau_{\mathrm{vac}})$ rather than $V_j(t, \tau')$

- *Multivariant vaccination at time t_{vac}.* An individual S or A vaccinated with a multi variant concoction at time $\tau \in [t_v^{\mathrm{on}}, t_v^{\mathrm{off}}]$, say with variant $j_1, \ldots, j_\nu$, will have their disease status updated with regard to all these variants, as in the dominant variant case.

A.2.2 Infectious contacts

Infectious individuals are assumed to make $\hat{\kappa}$ *effective contacts* each time period; where effective contacts are those that are sufficiently close and of a sufficiently long duration to constitute a "risk of transmission." This rate is either a constant κ_0, or in stochastic implementations drawn from a Poisson distribution with mean κ_0, or in adaptive formulations (e.g., under social distancing behaviour) is a function of the severity of the ongoing outbreak. We also assume at time t that under a random contact process, proportion $\frac{\hat{\kappa}(t)N_\mathrm{S}(t)}{N_0-N_\mathrm{D}(t)}$ and $\frac{\hat{\kappa}(t)N_\mathrm{A}(t)}{N_0-N_\mathrm{D}(t)}$ of these contacts will respectively be with susceptible and with uniquely identified agents, although only $\frac{\hat{\kappa}(t)(N_\mathrm{A}(t)-N_\mathrm{E}(t)-N_\mathrm{I}(t))}{N_0-N_\mathrm{D}(t)}$ of those will be susceptible to infection with a new variant or reinfection with the same variant.

In the adaptive case, we assume $\kappa(t)$ decreases from κ_0 as the proportion of infectious individuals, $N_\mathrm{I}(t)/(N_0 - N_\mathrm{D}(t))$, increases such that $\kappa(t) = \kappa_0/2$ when $N_\mathrm{I}(t)/(N_0 - N_\mathrm{D}(t)) = p_\mathrm{I}^{\mathrm{half}}$. For convenience of implementation, however, we define the following "switching" (as apposed to hyperbolic) function

$$\kappa(t) = \begin{cases} \dfrac{\kappa_0}{1+\left(\frac{N_\mathrm{I}(t)}{N_0-N_\mathrm{D}(t)}\big/p_\mathrm{I}^{\mathrm{half}}\right)^2} & \text{when } p_\mathrm{I}^{\mathrm{half}} > 0 \\[2ex] \kappa_0 & \text{when } p_\mathrm{I}^{\mathrm{half}} = 0 \end{cases} \tag{A.7}$$

even though, from a continuity point of view, the top part of this expression implies that $\kappa(t) \to 0$ at $p_\mathrm{I}^{\mathrm{half}} \to \infty$.

A.2.3 Probability of infection

In deriving a probability $\pi_{ih,j\ell}^{\mathrm{inf}}$ of an agent A_h being infected with variant ℓ by an agent A_i who is infectious with major variant j, we concatenate (i.e., multiply together) several process, each of which involves nominal constants. Thus, in all but one of these processes, the scaling of these constants can be normalized and given a relative set of values across variants though one set of constants though relative, will ultimately all be scaled by fitting the model to real data. In our treatment below, constants associated with shedding and persistence will be scaled while those associated with within-host replication will be kept unscaled to be ultimately fitted to data. In particular, the parameters $\bar{\beta}_j$ associated with pathogen transmission (i.e., from contact to the start of within host replication—see Fig. 1) will be scaled by fitting to epidemiological data, while the relative values for the different variants regarding pathogen shedding and environmental persistence can be fitted to experimental data collected to set values of these processes when considered on their own.

Pathogen shedding. We assume that shedding is affected by the immune state of the infector A_i and thus posit the shedding rates below for this individual when its major infectious variant is j. In general, we have a matrix of shedding rates $\bar{\zeta}_{j\ell}$ before accounting for immunity and cross immunity that is specific to agent A_i. Immunity and cross-immunity act to reduce shedding rates through functions $\phi_{ij}(t) \in [0,1]$ that are computed in terms of A_i's waning functions ω_{im} with respect to variant m and a matrix of cross-immunity values c_{jm} that have been normalized so that $c_{jj} = 1$ for $j = 0, ..., 2^J - 1$ and $c_{jm} \in [0,1]$ for

218 $j, m = 0, ..., 2^J - 1$. Specifically, we define agent-specific *immunity modifying*
219 *functions*

$$\phi_{ij}(t) = \prod_{m=0}^{2^J - 1} \left(1 - c_{mj}\omega_{im}(t) \right) \tag{A.8}$$

220 and assume that the shedding rates can be expressed as

$$\zeta_{ij\ell}(t) = \bar{\zeta}_{j\ell}\phi_{i\ell} \qquad \ell = 0, ..., 2^J - 1 \tag{A.9}$$

Environmental persistence. The persistence of pathogens in the environment
are known to be impacted by humidity, temperature, airflow, and the surface
properties of fomites [51]. This, and other factors relating the effects of weather
on contact rates and efficacy, may result in overall pathogen transmission having
a seasonal component to it [52]. In particular, viral persistence indoors may
be much greater than outdoors, with a greater proportion of indoor contacts
taking place during cold or wet weather. Thus the most appropriate place
to introduce seasonal effects into epidemic processes is through contact rates
and environmental persistence cycling over time with a period of one year (or
even half-a-year if two comparatively spaced rainy seasons occur, as in some in
tropical locations [53]) and an amplitude obtained by fitting parameters to data.
Thus, in our model, we introduce constants $\bar{\eta}_\ell$, $\delta_{\text{season}} \in (0, 1)$, k (appropriately
scaled, depending on the units of time) and θ and assume that

$$\eta_\ell(t) = \bar{\eta}_\ell \left(1 + \delta_{\text{season}} \sin\left(\frac{2\pi t}{k} + \theta \right) \right) \qquad \ell = 0, ..., 2^J - 1 \tag{A.10}$$

The case $\delta_{\text{season}} = 0$ corresponds to constant values $\eta_\ell(t) = \bar{\eta}_\ell$ for all t, while
if $\delta_{\text{season}} = 1$ we get the largest possible fluctuation between 0 and $2\bar{\eta}_\ell$. The
constant k relates to the time units so we get one cycle per year, and θ shifts
the cycle to set the points in time at which the maximum and minimum values
of $\eta_\ell(t)$ occur.

Variant transmission. In the context of a standardized dose (which will be
modified by multiplying the variant *effective contact* and transmission by both
pathogen shedding and environmental persistence functions), the differential
rates of variant transmission, which we denote by $\beta_{h\ell}$, will depend on a constant
variant transmission rate parameter $\bar{\beta}_\ell$ modified by a function that represents
the immune state of the infectee at time t: viz., recalling SOF Eq. A.8

$$\beta_{h\ell}(t) = \bar{\beta}_\ell \phi_{h\ell}(t), \quad \ell = 0, ..., 2^J - 1 \tag{A.11}$$

246 Probability of infection. Using a competing rates formulation [37] to compute
247 the probability of infection as a concatenation of the process of infector shedding
248 (ζ), environmental persistence (η) and transmission rates (β), we obtain

$$\pi_{ih,j\ell}^{\inf}(t) = \frac{\zeta_{ij\ell}(t)\eta_\ell(t)\beta_{h\ell}(t)}{\sum_{m=0}^{2^J - 1} \zeta_{ijm}(t)\eta_m(t)\beta_{hm}(t)} \left(1 - e^{-\zeta_{ij\ell}(t)\eta_\ell(t)\beta_{h\ell}(t)} \right), \quad \ell = 0, ..., 2^J - 1 \tag{A.12}$$

A.2.4 Within-host processes

If after receiving an initial infectious dose of pathogen, an individual is infected primarily with variant ℓ, then we expect this variant to dominate unless intrinsic mutational processes are high (which is not the case for COVID-19) or the individual has some immunity to this dominant variant. In the latter case the situation is ripe for an "idealized escape mutation," that is one that evades the immune system completely, to arise.

   If we nominally set the relative rate at which an individual invaded by variant ℓ has an infection dominated by variant ℓ (i.e., ℓ in the terminology of [54] is the major variant of the infection) to be $(1 - \mu)$, then the probability that one of the other variants is $\ell' \neq \ell$ is μ (in the case of COVID we assume that $\mu > 0$ is very close to 0—e.g. of order 10^{-3} to 10^{-6}—while for viruses lacking error correcting machinery it can be considerably larger and of the order 10^{-1}). We can partition the latter probability according to a set of comparative variant within-host replication rates $\lambda_{\ell'}$, each moderated by its immune state function $\phi_{h\ell'}$ and a normalizing factor $\frac{1}{\sum_{\forall m \neq \ell} \lambda_m \phi_{hm}}$ to obtain

$$
\pi_{h\ell\ell'}^{\text{inv}}(t) = \left\{
\begin{array}{ll}
1 - \mu & \text{for } \ell' = \ell \\
\mu \left(\frac{\lambda_{\ell'} \phi_{h\ell'}}{\sum_{\forall m \neq l} \lambda_m \phi_{hm}} \right) & \text{for } \ell' \neq \ell
\end{array}
\right.
\tag{A.13}
$$

We stress that the parameter μ pertains to generating the probability for the transmission of mutants and is not an actual mutation rate for the virus (e.g., the host may have some mechanisms for removing most of the mutants before transmission of remaining variants occurs).

A.2.5 Pathogen progression equations

Probability that infector A_i with major variant j will result in infectee A_h express ℓ' as its major variant is

$$
\pi_{ih,j\ell'}(t) = \sum_{\ell=0}^{2^J-1} \pi_{ih,j\ell}^{\text{inf}}(t) \pi_{h\ell\ell'}^{\text{inv}}(t), \quad \ell = 0, ..., 2^J - 1
\tag{A.14}
$$

A.2.6 Single-variant case

In the single-variant case ($J = 0$), the waning immunity equation SOF Eq. A.6 reduces to (dropping the redundant index $j = 0$, and noting that the existence of a value τ_i implies A_i has been infected at time τ_i in the past)

$$
\omega_i(t) = \left\{
\begin{array}{ll}
0 & \text{if } A_i \text{ has never been infected} \\
\dfrac{1}{1 + \left((t - \tau_i - \sigma_{\text{I}} - \sigma_{\text{E}})/t^{\text{half}} \right)^{\sigma}} & \text{if } t \geq \tau_i + \sigma_{\text{I}} + \sigma_{\text{E}} \\
1 & \text{if } t < \tau_i + \sigma_{\text{I}} + \sigma_{\text{E}}
\end{array}
\right.
\tag{A.15}
$$

(recall we set $\sigma = 4$) and the modifying immunity functions ϕ_{ij} (SOF Eq. A.8) collapse to 1, which implies that the pathogen shedding functions $\bar{\zeta}_{i\ell}$ (SOF

²⁷⁸ Eq. A.9) collapse to 1. Without loss of generality, we can also assume a single-
²⁷⁹ variant value of $\eta = 1$ in SOF Eq. A.10, which implies that the probability of
²⁸⁰ infection (SOF Eq. A.12) reduces to

$$\pi_{ih}^{\mathrm{inf}}(t) = 1 - e^{-\bar{\beta}(1-\omega_h(t))} \tag{A.16}$$

²⁸¹ Further, since in the single-variant case there are no mutations to consider, it
²⁸² follows from SOF Eq. A.13 that $\pi_{h\ell\ell'}^{\mathrm{inv}}(t) = 1$ for all h and we finally have that
²⁸³ $\pi_{ih}(t) = \pi_{ih}^{\mathrm{inf}}(t) = 1 - e^{-\bar{\beta}(1-\omega_h(t))}$ (SOF Eq. A.14) for all h.

²⁸⁴ A.3 Simulation algorithm

²⁸⁵ 1. **Parameters selected at the start of a simulation**

²⁸⁶ (a) N_0: Number of individuals in the population. Assumed to be fixed
²⁸⁷ over time (i.e., the population is closed), but partitioned into sets **S**,
²⁸⁸ **A** and **D** with respectively $N_S(t)$, $N_A(t)$ and $N_D(t)$ individuals in
²⁸⁹ each set and satisfying SOF Eq. A.1.

²⁹⁰ (b) J: The $\log_2$ of the number of possible variants indexed by $j =$
²⁹¹ $0, \cdots, 2^J - 1$

²⁹² (c) $\bar{\beta}_j$: variant dependent transmission parameters (the process between
²⁹³ contact and the start of variant replication and nominally equivalent
²⁹⁴ to transmission in SEIR models—see Fig. 1) for pathogen variant j

²⁹⁵ (d) t_j^{half}: The time it takes for immunity to variant j to have waned by
²⁹⁶ half.

²⁹⁷ (e) σ_{E_j}: The time it takes from initial infection for an infected individual
²⁹⁸ to become more likely to become infectious than remain infected
²⁹⁹ without being infectious.

³⁰⁰ (f) σ_{I_j}: The additional time it takes beyond σ_{E_j} for an infectious indi-
³⁰¹ vidual to more likely transition beyond being infectious than remain
³⁰² infectious.

³⁰³ (g) p_{α_j}: The proportion of individuals leaving the infectious category
³⁰⁴ that die, which implies that $1 - p_{\alpha_j}$ is the proportion that become
³⁰⁵ immune.

³⁰⁶ 2. **Initialization**

³⁰⁷ (a) Set up pathogen list (see Eq. A.2)

³⁰⁸ (b) Initialize the simulation by setting $t = 0$ and creating the agent list
³⁰⁹ $\mathbf{A}(0)$ one infectious and $N_0 - 1$ susceptible agents.

³¹⁰ 3. **Time t: vaccination loop.**

³¹¹ (a) Carry out the vaccination process before going into the rest of the
³¹² loops with the updated S and A sets after the vaccinations.

³¹³ 4. **Time t: contact loop.** Set up contacts for the current round of en-
³¹⁴ counters at time t (i.e., the inner agent-driven contact loop within the
³¹⁵ outer time-driven loop) and tag for outer loop update of disease status, as
³¹⁶ follows:

(a) *Numbers in various sets and associated index sets.* Identify the number of individuals $N_S(t)$, $N_A(t)$ and $N_D(t)$ in sets **S**, **A** and **D** at time t respectively, as well as the number of exposed (but not yet infectious) agents $N_E(t)$, infectious agents $N_I(t)$ and identified non-infected agents $N_{A_S}(t) = N_A(t) - N_I(t) - N_E(t)$. Break down the infectious agents tally into the number of agents N_{I_j} infectious with variant $j = 0, 1, ..., 2^J - 1$. We will also need the index sets $\mathbb{I}_{A_S}$ and $\mathbb{I}_{I_j}(t)$, $j = 0, ..., 2^J - 1$ at time t.

(b) *Infectious contacts with each group.* The rate at which any individual contacts other individuals per unit time is given by the contact rate parameter $\kappa > 0$. Assuming random contact events over one unit of time, the actual number of individuals that agent A_i contacts at time t is then given by

$$\hat{\kappa}_i(t) \sim \texttt{POISSON}[\text{mean} = \kappa(t)]$$

Of these, proportions

$$\pi_{iS} = \frac{N_S(t)}{N_0 - N_D(t)} \tag{A.17}$$

and

$$\pi_{iA} = \frac{N_A(t) - N_I(t) - N_E(t)}{N_0 - N_D(t)} \tag{A.18}$$

are expected to come from susceptibles in the sets $\mathbf{S}(t)$ and $\mathbf{A}_S(t)$ (see Eq. A.5) respectively. Thus the actual number of contacts in set $\mathbf{S}(t)$, $\mathbf{A}_S(t)$, and $\mathbf{E}(t) \cup \mathbf{I}(t)$ are

$$\left(\hat{N}_i^S(t), \hat{N}_i^{A_S}(t), \hat{N}_i^E(t) + \hat{N}_i^I(t) \right) = \tag{A.19}$$
$$\texttt{Multinomial}\left[\hat{\kappa}_i; \pi_{iS}, \pi_{iA}, 1 - \pi_{iS} - \pi_{iA} \right]$$

We note that only $\hat{N}_i^S(t)$ and $\hat{N}_i^{A_S}(t)$ are of interest because individual in states E and I cannot be reinfected. Also, we make the assumption below that the first infection that an individual in set **A** contracts in this contact loop, is the one that counts (i.e., there will be no simultaneously infections with multiple variants). Finally, since contacting individuals is tantamount to sampling with replacement, the number of unique contacts (i.e., all multiple contacts are counted as a single contact) that agent A_i has with individuals in the set **S** is $\hat{N}_i^S(t)$ reduced by excluding multiple contacts (which under a random contact model is a negative exponential correction) to obtain

$$N_i^{S*}(t) = \min \left\{ \hat{N}_i^S(t), \texttt{Binomial}\left[\hat{\kappa}_i(t), e^{-\hat{\kappa}_i(t)/\hat{N}_i^S(t)} \right] \right\} \tag{A.20}$$

Thus if $\hat{\kappa}_i(t) << \hat{N}_i^S(t)$, $N_i^{S*}(t)$ is expected to be very close to the upper value $\hat{\kappa}_i(t)$. On the other hand, if $\hat{\kappa}_i(t) \approx \hat{N}_i^S(t)$, then $N_i^{S*}(t)$ is expected to be around $\hat{\kappa}_i(t)/e \approx 0.37\hat{\kappa}_i(t)$. Additionally, after dealing with each agent i reduce in the size of $N_S(t)$ to take account of those agents that had been infected by agent A_i and had now entered the ranks of the set **A**.

(c) *Identify all infectious agents and their pathogens variants.* Among all agents in the set $\mathbf{A}(t)$ (Eq. A.4), identify those that have an infectious variant I_j for some $j = 0, \cdots, 2^J - 1$. Thus, if the number of infectious agents with infectious variant j is $N_{I_j(t)}$ then consider the set

$$\mathbf{I}_j(t) = \{A_{i_1}^j(t), A_{i_2}^j(t), \ldots, A_{N_{I_j}}^j(t)\}$$

with index set

$$\mathbb{I}_{I_j}(t) = \{i_{1_j}, \cdots, i_{N_{I_j}(t)}\}$$

Initially, most of these sets will be empty, but will fill in over time.

(d) *Susceptible contacts.* The probability that an agent A_i with a variant j major infection infects a susceptible (nominally denoted by individuals of type A_0) who then becomes infectious with dominant variant ℓ' is given by the probability $\pi_{i0, j\ell'}$ computed in Eq. A.14, which itself relies on expressions Eq. A.7-A.13. The actual number of individuals in the set $\mathbf{S}$ will make effective contact with one more infectious individuals is $N_i^{S*}(t)$ obtained using Eq. A.20. Thus, from a multinomial drawing, we can now generate the number of newly exposed individuals, $N_{0\ell'}^{E+}(t+1)$ (the "+" is used to denote these are newly added and the "0" that they are coming from the set $\mathbf{S}$), with major variant ℓ' at time $t + 1$, have been infected by agent A_i with major pathogen variant j on the time interval $[t, t+1)$:

$$
\begin{aligned}
(\hat{N}_{00}^{E+}(t), \cdots, \hat{N}_{02^J - 1}^{E+}(t)) \quad &\sim \quad \text{(A.21)}\\
\texttt{Multinomial} &\left[N_i^{S*}(t); \pi_{i0, j0}(t), \cdots, \pi_{i0, j\, 2^J - 1}(t) \right]
\end{aligned}
$$

These individuals will be used to update list of currently infected individuals in the sets $\mathbf{A}_{E_j}$, $j = 0, ..., 2^J - 1$ at time t+1, which is computed in the outer loop computation, as presented below. We also note that the probabilities in the above multinomial add to less than 1, so that at the end of the drawing a proportion of the individuals $N_i^{S*}(t)$ remain uninfected.

(e) *Agent contacts.* The number of agents $\hat{N}_i^{AS}(t) \in \mathbb{I}_{A \setminus (E \cup I)}$ that come into contact with agent A_i over the interval $(t, t + 1)$ is given by Eq. A.19. This number is drawn from the set $\mathbb{I}_{A \setminus (E \cup I)}$ with replacement and the following multinomial computation is used to determine how to update agent A_h at time $t+1$ when coming into contact with agent A_i on the interval $(t, t+1)$ using the probabilities of transmission given in Eq. A.14. Specifically, agent A_h will become infected with major variant ℓ' at time $t + 1$ is determined by the multinomial drawing

$$A_h \in \mathbf{A}_{E_j} \text{ for some } j \sim \texttt{Multinomial} \left[1; \pi_{ih, j0}(t), \cdots, \pi_{ih, j\, 2^J - 1}(t) \right] \quad \text{(A.22)}$$

We note here that since the agents A_h, $h \in \mathbb{I}_{A \setminus (E \cup I)}$ are drawn with replacement as the computation proceeds and the agents A_i, $i \in \mathbb{I}$ are cycled through, if a previously drawn A_h is drawn again, but has already

been infected in the current round then we ignore the latest event, but keep
the previous infection event intact. To obviate bias in this procedure, we
need cycle through the agents $A_i, i \in \mathbb{I}$ at random rather than in numerical
order.

5. **Time t: disease progression loop.**

   (a) *Individuals in $\mathbf{A}_E$ at time t.* An individual $A_i \in \mathbf{A}_E$ at time t and in
       state $E_j(t, \tau_i)$, $j = 0, ..., 2^J - 1$, becomes either an individual in state
       $E_j(t + 1, \tau_i)$ with probability

$$\pi_{E_j}(t) = \frac{1}{1 + \left(\frac{t - \tau_i}{\sigma_{E_j}}\right)^4} \qquad (A.23)$$

   or transfers to state $I_j(t+1, \tau_i)$ with probability $\left(1 - \pi_{E_j}(t)\right)$ thereby
   entering class $\mathbf{A}_I$ at time $t + 1$.

   (b) *Individuals in $\mathbf{A}_I$ at time t.* An individual $A_i \in \mathbf{A}_I$ at time t and in
       state $I_j(t, \tau_i)$, $j = 0, ..., 2^J - 1$, becomes either an individual in state
       $I_j(t + 1, \tau_i)$ with probability

$$\pi_{I_j}(t) = \frac{1}{1 + \left(\frac{t - \tau_i}{\sigma_{E_j} + \sigma_{I_j}}\right)^4} \qquad (A.24)$$

   or leaves the set $I_j(t + 1, \tau_i)$ with probability $\left(1 - \pi_{I_j}(t)\right)$. In this
   latter case, the individual either dies with probability p_{α_j} or enters
   the state $V_j(t+1, \tau_i)$ at time $t+1$ with probability $1 - p_{\alpha_j}$ The total
   number of individuals dying over the interval $[t, t + 1)$ is noted as
   having a value $\Delta N_D(t)$.

6. **Time $t + 1$: outer loop update.** The outer loop records all the events
   that took place in the contact and disease progression loops and updates
   the agents state at the next time step. It also updates all other states as
   follows.

   (a) *Individuals in $\mathbf{A}_S$ at time t.* For the $N_S(t)$ individuals in $\mathbf{A}_S$ at time
       t, we have $N_{0j}^{E+}(t)$ enter set $\mathbf{A}_{E_j}(t + 1)$ and we update

$$N_S(t + 1) = N_S(t) - \sum_{j=0}^{2^J - 1} N_{0j}^{E+}(t)$$

   where Eq. A.20 ensures that $N_S(t + 1) \geq 0$

   (b) *Individuals in $\mathbf{A}_S$ that are infected again over $[t, t + 1)$.* These in-
       dividuals can become reinfected as calculated in the contact loop.
       Those that become reinfected with variant j, $j = 0, ..., 2^J - 1$ enter
       state $\mathbf{E}_j(t + 1, t + 1)$ at time $t + 1$.

   (c) *Updating the immunity of individuals in $\mathbf{A}_S$.* Every individual within
       $\mathbf{A}_S$ at time t must have its immunity status updated so that for
       $j = 0, ..., 2^J - 1$, if A_i is in state $V_j(t, \tau_{ij})$ at time t then it transfers
       to state $V_j(t+1, \tau_{ij})$ at time $t+1$, even if reinfected, as in b.) above.

(d) *Transfer from* **S** *to* **A**. The $\hat{N}_{0j}^{\mathrm{E}}(t)$ computed in Eq. A.21 become newly listed members of the set **A** by entering state $\mathbf{E}_j(t+1, t+1)$, $j = 0, ..., 2^J - 1$. This involves updating the equations for $N_{\mathrm{S}}(t)$ and $N_{\mathrm{A}}(t)$, including taking account of the number of individuals $\Delta N_{\mathrm{D}}(t)$ that died from the disease in the immediate time period, i.e.:

$$
\begin{aligned}
N_{\mathrm{S}}(t+1) &= N_{\mathrm{S}}(t) - \sum_{j=0}^{2^J-1} \hat{N}_{0j}^{\mathrm{E}}(t) \\
N_{\mathrm{A}}(t+1) &= N_{\mathrm{A}}(t) + \sum_{j=0}^{2^J-1} \hat{N}_{0j}^{\mathrm{E}}(t) - \Delta N_{\mathrm{D}}(t) \qquad \text{(A.25)} \\
N_{\mathrm{D}}(t+1) &= N_{\mathrm{D}}(t) + \Delta N_{\mathrm{D}}(t)
\end{aligned}
$$

(e) Along with input parameter values $t_{\mathrm{vac\_on}} \geq 0$, $t_{\mathrm{vac\_off}}$ and $p_v \in [0, 0.1]$, we also need to specify the valency of the vaccination by selecting 1 to 4 numbers that take on values $0, ..., 2^J - 1$ (if more valencies are needed than 4, then the platform needs to be modified accordingly). We also need specify whether N_{select} will just be individuals in the set $\mathbf{S}(t)$ ($N_{\mathrm{select}} = N_{\mathrm{S}}$) or will be any individual other than those in the set $\mathbf{A}_{\mathrm{I}}(t)$ ($N_{\mathrm{select}} = N_{\mathrm{S}} + N_{\mathrm{A}} - N_{\mathrm{I}}$).

In Algorithm 1 we summarise the steps of the simulation algorithm, as described in this section. On the right we report the name and numbering of the subsections while in the for loops we list the various steps respecting the item letters. Note that technical steps not explicitly described in the text (e.g. store updates, store set progression) do not present letters or numbers. The time set is defined with T while to describe temporal progression of set $\mathbf{S}, \mathbf{A}$ and $\mathbf{D}$ we use the symbols $\mathcal{S}, \mathcal{A}, \mathcal{D}$ respectively.

A.4   Estimation of R_0.

In a finite population, a pathogen can emerge from a single infection with probability $p_{\mathrm{outbreak}} = 1 - 1/R_0$ if $R_0 > 1$, otherwise an outbreak will not occur [42]. Thus we can estimate R_0 if we have an estimate of p_{outbreak} and the use the following relationship to compute R_0

$$
R_0 = \frac{1}{1 - p_{\mathrm{outbreak}}} \qquad \text{(A.26)}
$$

For the set of parameters listed in Table 2, from 100 runs (runtime seed goes from 0 to 99 in 100 separate simulations) of the single strain case, we estimated $p_{\mathrm{outbreak}} \approx 0.68$ from the the proportion of simulations that had positive prevalence after 100 days. From Eq. A.26 this implies that $R_0 \approx 3.1$, with a 95% confidence interval of $R_0 \in [2.4, 4.3]$ (this of course can be narrowed down with additional simulations, but a more precise estimate is not particularly relevant to our illustrative results).

Algorithm 1: Summary of simulation algorithm

---

input N_0, J, $\bar{\beta}_j$, t_j^{half}, σ_{E_j}, σ_{I_j}, p_{α_j}, $j = 0, ..., 2^J - 1$ // 1)`parameters`

$\{(\bar{\eta}_j, \bar{\beta}_j, \lambda_j, p_{\alpha_j};\ \zeta_{jm}$ and c_{mj} for $m = 0, ..., 2^J - 1)$ // 2a) `pathogen`

$\big|\ j = 0, ..., 2^J - 1\}$ // `list`

$t = 0, N_{\mathrm{I}}(0) = 1, N_{\mathrm{S}}(0) = N_0 - 1$ // 2b) `initialization`

for t *in* T **do**

    if $N_{\mathrm{I}} > 0$ **then**

        for *agent in* $\mathbf{S} \cup (\mathbf{A} \setminus \mathbf{I})$ **do**   // 3) `vaccination loop`

            3a) Vaccination process

            Update N_{S} and N_{A}

        for *agent in* $\mathbf{I}$ **do**   // 4) `contact loop`

            4a) Numbers in various sets and associated index sets

            4b) Infectious contacts with each group

            4c) Identify all infectious agents and their pathogens variants

            4d) Susceptible contacts

            4e) Agent contacts

            Store updates

        for *agent in* $\mathbf{E}$ **do**   // 5a) `disease progression loop`

            5a) Individuals in $\mathbf{A}_{\mathrm{E}}$ at time t

            Store updates

        for *agent in* $\mathbf{I}$ **do**   // 5b) `disease progression loop`

            5b) Individuals in $\mathbf{A}_{\mathrm{I}}$ at time t

            Store updates

        Updates from loops 4), 5a) and 5b)

        6a) Individuals in $\mathbf{A}_{\mathrm{S}}$ at time t // 6) `updates in outer loop`

        6b) Individuals in $\mathbf{A}_{\mathrm{S}}$ that are infected again over $[t, t+1)$

        6c) Updating the immunity of individuals in $\mathbf{A}_{\mathrm{S}}$

        6d) Transfer from $\mathbf{S}$ to $\mathbf{A}$

        6e) Specify the valency of the vaccination

        $\mathcal{S}[t] \leftarrow \mathbf{S}(t)$ // `store set progression`

        $\mathcal{A}[t] \leftarrow \mathbf{A}(t)$

        $\mathcal{D}[t] \leftarrow \mathbf{D}(t)$

    return $\mathcal{S}, \mathcal{A}, \mathcal{D}$

B RAMP Details

B.1 General description

An open and expressive design of the model platform aids in and encourages exploration and experimentation. The RAMP design augments a desktop simulation platform with several novel features that increase flexibility and expressiveness, and promote experimentation and interoperability with other platforms. These include an API ("application programming interface") fully supporting remote operation and direct retrieval of data for external processing on other platforms, such as Python, Javascript or the R statistical platform. The API can also be accessed by an onboard scripting interface that uses the Nashorn Javascript engine.

Additionally, using a novel design, elements of the internal algorithm are exposed for possible reprogramming in a secure fashion that will not damage the overall system. These runtime alternative modules (RAMs) may also be controlled from the API to facilitate selective algorithm redefinition during the run of the simulation.

Use of the RAMP features require some experience with scripting and/or Java coding, however the resulting modifications to the algorithm can be of great significance. The RAM platform is implemented to support program redefinition with no risk to damaging the underlying code base. It should be accessible to anyone with moderate scripting experience.

A major goal of the RAMP project is to prepackage these functionalities so that they can be readily deployed as part of simulation system design. This goal has been partially realized with respect to the RAM platform: annotations can be added to the simulator's source code that direct the automatic generation of Java code to integrate into the simulations' source and provide the functionality.

The following discussion assumes some familiarity with script or program development.

B.2 Runtime alternative modules

Figure B.1 shows the RAM redefinition frame. The available RAMs appear as radio buttons along the bottom of the frame. Each RAM is a set of options for defining a relatively short Java method implementing some key aspect of the simulation algorithm. For example, included in this simulation are the implementation for cross immunity given in Eq. 1; the implementation for β given in Eq. A.11; and the implementation for ϕ given in Eq. A.8; etc. Each RAM initially contains only a single option, Option 0, the default, internally defined implementation. Option 0 cannot be edited and appears for reference purposes only.

Additional options may be added to each RAM containing code redefining the method. Two editor panes and one console pane are stacked in the frame and display the code and output of the RAM. These panes show the content associated with the currently selected RAM and option. The top editor pane contains the code for the method being redefined. The second editor pane contains definitions of any new help functions required by the definition in the top

Figure B.1: RAM frame shows the implementation of a generic nearest-neighbor cross-immunity formulation **C** as the default. In the red-bordered insets are the cascading cross-immunity without (blue highlighted radio button 1) and with an idealized escape mutation (blue highlighted radio button 2), as formulated in Eqs. 1 and 2 respectively. Note the "+" button which allows for an unlimited number of alternatives to be set up using consecutive integer numbers for the new radio-buttons that appear and pertain to the selection of each alternative. Also, note the bottom list of functions that can be altered at runtime. The "load default" button on the upper left-hand side allows the user, when starting a new alternative, to insert the default code (which is immutable in radio-button 0) as a starting point. The frame also documents a list of terms in the upper panel that can be used to build any function.

⁴⁸³ pane. The console pane contains messages and output that are useful during the
⁴⁸⁴ development of the option. For convenience, a "Load Default" button initializes
⁴⁸⁵ the editor to an editable version of the Option 0 default to use as a starting
⁴⁸⁶ point.

⁴⁸⁷   Figure B.1 shows the Option 0 default definition for the cross immunity
⁴⁸⁸ matrix function, as described by Eq. 1. Clicking the "+" button produced two
⁴⁸⁹ new options, which appear in the insets. These option implement the alternative
⁴⁹⁰ cascading cross immunity schemes presented in Eqs. 1 and 2. code appears
⁴⁹¹ below:

```
492      double crossImmune(int j, int k)  {
493          if (l == j) return 1;
494          if (j < pathSize()/2 && l >= pathSize()/2) return 0;
495          return Math.pow(Params.cImmune(), Tools.hdist(j, l));
496      }
```

Note that we have substituted the function `pathSize` for a hard-coded value of 63. `pathSize` returns the number of pathogens, allowing us to use this formulation for any choice of entropy. Documentation for `pathSize` is at the top of the window in the list of available help functions and parameters. There is also more extensive documentation in a separate user guide (see Fig. B.2).

J-RAMP SEIVD IBM A-Mod Guide

rms wgetz

May 2021

ω (Equation 9)

$$\omega_{ij}(t) = \begin{cases} 0 & \text{if } V_j \text{ is null} \\ \dfrac{1}{1 + \left((t - \tau_{ij} - \sigma_\text{I} - \sigma_\text{E})/t_j^{\text{half}}\right)^\sigma} & \text{if } t \geq \tau_{ij} + \sigma_\text{I} + \sigma_\text{E} \\ 1 & \text{if } t < \tau_{ij} + \sigma_\text{I} + \sigma_\text{E} \end{cases}$$

Code

```
double omega(int i, int j)
{
  if (i == 0) return 0.0;        // Special case; A_0 never infected
  InfectedAgentState astate = getStateOf(i, j);
  if (astate == null || !(astate instanceof V)) return 0.0;
  double tau =  tau(i,j);
  double sigI = sigmaI(j);
  double sigE = sigmaE(j);
  double timeSinceInfect = tau + sigI + sigE;
  if (time() <= timeSinceInfect) return 1.0;
  return 1/(1 + Math.pow((time() - timeSinceInfect)/tHalf(j), Params.sigma()));
}
```

Notes

`astate = getStateOf(i,j)`	astate is assigned to a Java `InfectedAgentState` object for agent i with respect to pathogen j. `InfectedAgentState` objects can either be state `E`, `I`, `V` or `null` (the latter for never-infected or dead agents.)
`astate == null || !(astate == V)`	astate is something other than state V.
`tau(i,j)`	$= \tau_{ij}$.
`sigmaI(j)`	$= \sigma_\text{I}$.
`sigmaE(j)`	$= \sigma_\text{E}$.
`tHalf(j)`	$= \tau_j^{half}$.
`time()`	$= t$.
`Params.sigma()`	$= \sigma$.

Figure B.2: A description from our User Guide of the immunity waning function ω.

The platform duplicates a mini-development environment for building alternative definitions. Once code has been entered the "Compile" button checks the legality of the code and makes it available for use at runtime. Legally com-

⁵⁰⁵ piled code will produce a "Compilation Successful" message. Errors will appear
⁵⁰⁶ with line numbers if they occur. Once the code is legal, the "Test" button can
⁵⁰⁷ be used with actual parameters entered into the small text fields to determine
⁵⁰⁸ correctness of the code. It is also possible to include `print` and `println` state-
⁵⁰⁹ ments in the code during development to further check correctness. Output
⁵¹⁰ from print statements will appear in the bottom console window. The entire
⁵¹¹ RAM set can be saved and will reappear during subsequent launches of the
⁵¹² simulator platform.

⁵¹³   To use an alternate RAM definition at runtime simply select the dM-SEIRed
⁵¹⁴ option. (Selected options will be restored from a saved RAM set during subse-
⁵¹⁵ quent launches.) The system will compile any uncompiled code the first time it
⁵¹⁶ is accessed. If an error occurs during a runtime compilation an alert will notify
⁵¹⁷ the user that the system is returning to the default definition of that RAM. At
⁵¹⁸ no time is the internal logic of the program overridden.

⁵¹⁹   Finally, RAM option selection is part of the API described in the next sec-
⁵²⁰ tion. This means that a script may run a simulation selecting different options
⁵²¹ at different points in time, using logic that considers the state of the model. For
⁵²² example, such an adaptive protocol might be appropriate for determining the
⁵²³ contact rate κ.

B.3 Application programming interface

⁵²⁵ The API is a simple bytecode[1] called BPL (Blackbox Programming Language)
⁵²⁶ that addresses all available user interactions with the simulator. Instructions
⁵²⁷ fall into three categories: parameter assignment and retrieval; simulator oper-
⁵²⁸ ation; and data retrieval. A complete list of instructions is shown in Fig. B.3.
⁵²⁹ Instructions are comprised of opcodes (e.g., `reset`, `step`, `get`) followed by 0
⁵³⁰ or more arguments. Every BPL operation returns a result, even if empty, for
⁵³¹ synchronization purposes. A string consisting of a sequence of opcodes and
⁵³² arguments may be submitted to the BPL interpreter, an example of which is
⁵³³ shown in the notes in Fig. B.3.

⁵³⁵ **Parameter assignment and retrieval.** Every user-configurable element (in-
⁵³⁶ cluding random number generator seeds) is addressed from BPL using a unique
⁵³⁷ three-letter "airport code" (see Table. B.31). Additionally, pathogens are ad-
⁵³⁸ dressed by their id number (0 to $2^J - 1$) and agent states using identifiers S, E,
⁵³⁹ I, V, DI+ and DD (the latter two represent ΔI and ΔD, respectively). RAM
⁵⁴⁰ options are addressed in `setOption` and `getOption` using the name of the RAM
⁵⁴¹ (e.g., "crossImmune"). Get and set operations can be used on each of these with
⁵⁴² the exception of ENT (variant entropy), which is read-only.

⁵⁴⁴ **Simulator operation.** Simulation runs begin by executing the BPL `reset`
⁵⁴⁵ instruction, followed by **step**, **run_for** or **run**. The BPL interpreter operates
⁵⁴⁶ synchronously with the simulator by waiting to process subsequent commands
⁵⁴⁷ during a simulation run. Operational instructions can be interspersed with pa-
⁵⁴⁸ rameter set/get or data retrieval to use in runtime decision-making. Note that

---

[1] a *bytecode* is computer source code that is processed immediately by a program, usually referred to as an interpreter or virtual machine.

the **reset** operation restores the simulator to its state at the time of the last
reset, so that no parameter changes made during a run are persistent.

Data retrieval Operations to obtain the current population in each state, and
to retrieve the runtime population history of each state and pathogen are also
included. These can be easily transformed into R data frames, for example, for
further analysis.

Scripting can be deployed using either one of the two on-board script inter-
preter interfaces, or remotely from another platform using drivers provided with
the simulator. The remote drivers use TCP/IP *sockets*. Sockets are integral to
Internet communication, and so are found on any system supporting the Inter-
net. In this case the simulator acts as a server fielding API requests from the
remote drivers.
On our main dashboard, we provide two scripting windows that are opened
using the "S On" and "JS On" buttons (see button second and third from left at
bottom of Fig. 2A). The former allows the user to write simulation driver scripts
directly as command strings. (The commands listed in Fig. B.3 are accessed
by pressing the "Command Reference" button in the "S On" window.) This
window is used primarily to test and monitor scripts intended to be deployed on
a remote platform. The JS window contains a Nashorn Javascript interpreter
enhanced to accept and execute BPL operations. Scripts can developed, saved,
and used to drive the simulator from this interpreter. For example, Fig. B.4, lists
the code used to implement the adaptive vaccination programs. The `SEIV` object
referenced in this code contains methods corresponding to the BPL operations
detailed in Fig. B.3.

Table B1: Airport codes for parameter and variables used in the model algorithm

Name	Math	Code	Name	Math	Code
Epidemic codes					
% mortality	p_α	MOR	transmission	β	XMT
env. persist.	η	PST	within-host replication	λ	INV
median latent period	σ_E	MLP	median infectious period	σ_I	MIP
population size	N_0	POP	contact rate	$\bar{\kappa}$	CPT
mutation rate	μ	MUR	abruptness of waning	σ	AOW
cross immunity	c	CIM	waning half-life	t^{half}	WHA
seas. trans. peturb	δ_{season}	STP	seas. trans. shift	θ	STS
seas. trans. period	k	PER	adap. contact param.	$p_{\mathrm{I}}^{\mathrm{half}}$	IPC
variant entropy	J	ENT	shedding rate	$\tilde{\zeta}$	SHD
-[2pt] mortality peturb	δ_α	MOP	transmission perturb	δ_β	TRP
Vaccination codes					
enable vaccination		VEN	vaccine on/off	$t_v^{\mathrm{on}}/t_v^{\mathrm{off}}$	VOO
variant valency type	VA#, #=1,..,4		selection composition		VCP
vaccinate susc. only		VSU	vaccinate non-infectious		NVI
vaccinate non-vacc.		VNV			

BPL Reference

Commands

reset	Resets simulation with initial slider/switch values.
restart	Resets simulation with current slider/switch values.
run_for T	Run the simulation from the current time for T steps.
run	Run the simulation for the number of steps set by the last run_for command.
step	Single-step the simulation one time unit.
get time	Returns current simulation time.
getLimit XXX	Returns lower and upper values of limit control labeled XXX on separate lines.
getPath XXX id	Returns value of parameter XXX in pathogen id.
getOption op	Returns the option number for operator op in the operator overrides.
get XXX	Returns value of non-limit control labeled XXX.
setLimit XXX lo hi	Sets the limit control XXX to limits lo hi.
setPath XXX id Y	Sets value of parameter XXX in pathogen id to Y.
setOption op Y	Sets option for operator op in the operator overrides to option number Y.
set XXX Y	Sets value of non-limit control XXX to Y.
pathPop id Z	id is a pathogen id and Z must be one of the agent state identifiers (S, E, I, V, DI+, DD). Returns the current population in state Z with respect to pathogen id.
totPop Z	Z must be one of the agent state identifiers (S, E, I, V, DI+, DD). Returns the total population in state Z.
timeTrail	Returns the array of timesteps for use in a table with other trail data.
pathTrail id Z	id is a pathogen id and Z must be one of the agent state identifiers (S, E, I, V, DI+, DD). The population array for that pathogen and for that state over time is returned.
popTrail Z	Z must be one of the agent state identifiers (S, E, I, V, DI+, DD). The array of the entire population over time for that state is returned.
sleep T	NMBPL processor sleeps for T milliseconds.
	(May be used for synchronization during longer simulations.)

Notes

- Commands without explicit return do not return a value
- get and set use the 3-letter "airport codes" associated with each control
- Commands may be sequenced; e.g.

      run_for 50 set XMT 1.5 run popTrail I

  will run for 50 timesteps, set the transmission paramter to 1.5, run for another 50, and return the 100 population values of I.
- Returned values are separated by newlines. When command sequences are sent remotely, left and right brackets (i.e. \[and \]) followed by newlines enclose the sequence of returned values, even if the sequence is empty; e.g.,

  [\n50\n100\n1000\n]

- When using trail: if embedded in a command sequence, this must be the only command that returns a value (since the array returned by each of them will be embedded in the set of answers returned by the command sequence.)
- Use the console to test command sequences before using them remotely.
- BPL uses TCP/IP sockets to implement a client-server protocol on the local host. Clients initiate a connection on a specified port (default is 8080) and transmit a command sequence; the SEIVAgent server replies with the result and closes the connection.
- Changes to the port number, if saved to Preferences, will reappear in subsequent uses. Multiple instances of Numerus can run concurrently using different ports. Changes will automatically restart the server.
- **Restart** button restarts the server.

Figure B.3: The list of Blackbox Programming Language (BPL) commands that can be used to write a simulation driver script, using the three-letter "airport codes" listed in Table A1 to access the parameters and variables in our coded algorithm. This list of commands can be accessed using the "Command Reference" button at the bottom of the Scripting Window.

Figure B.4: The JS scripting window accessed by selecting the "JS On" button in the main dashboard (see button second from left at bottom of Fig. 2A). The script shown here (broken into two columns 1-74 and overlaid over JS window) was used to execute the adaptive vaccination strategy discussed in the main text.

B.4 R Integration

As previously mentioned, the API supports remote control of the simulator from independent platforms using the operating system's socket interface[2]. Of particular interest is integration with the R statistical programming environment. An R-package called "seiv" acts as a driver by synchronously issuing BPL command strings and waiting for results. Consequently, a simulation can be driven entirely from within the R platform, treating the simulator as a "virtual package".

Fig. B.5 shows the code used to run the simulator multiple times with different random number generator seeds. Following each run, the time history of the population in the I, DI+ and DD states is extracted directly to an R data frame (without the need to save, for example, in a comma-separated list). At the end of the run sequence the data frame is used to build the plots shown in Fig. 3D & E.

R could be used in a more direct way by analyzing data at various points throughout a single run and adjusting parameters programmatically, similar to the adaptive vaccination strategy carried out in Javascript, only taking advantage of the R environment's powerful toolkit.

---

[2]By using internet sockets, the simulator and R platform could conceivably run on different systems.

```
1   library("seiv")
2   library(ggplot2)              R driver used to integrate SEIV-IBM J-RAMP into runs to generate plots
3   library(reshape)
4
5 - execSEIVRemote <- function(seed=0, sampleSize=165, ...) {        36
6     who = list(...)                                               37 - buildMSFrame <- function(l) {
7     if (length(who) == 0) who = list("I", "DI+", "DD")            38      means = numeric()
8     seiv$dispatch(paste("reset set RSD", seed, "run_for", sampleSize))  39      stds = numeric()
9     time <- 0:(sampleSize)                                        40 -     for (m in 1:nrow(l)) {
10    ans <- data.frame("Time"=time)                                41        smpl = as.numeric(l[m,2:ncol(l)])
11    top <- sampleSize+1                                           42        means[m] = mean(smpl)
12 -   for (z in who) {                                             43        stds[m] = sqrt(var(smpl))
13      nxt <- seiv$dispatch(paste("popTrail", z))                  44 -   }
14      if (length(nxt) < top) nxt = c(nxt, integer(top-length(nxt)))   45      data.frame("Time"=l[1], "µ"=means, "µ+σ"=means+stds,
15      ans = cbind(ans, nxt)                                       46              "µ-σ"=means-stds, check.names=FALSE)
16      names(ans)[length(names(ans))] = z                          47 - }
17 -   }                                                            48
18    ans                                                           49 - buildGraph <- function(l, title) {
19 - }                                                              50      msFrame <- buildMSFrame(l)
20                                                                  51      molten = melt(msFrame, id.vars="Time")
21 - multiSEIV <- function(runs=3, sampleSize=165) {                52      ggplot(molten, aes(x=Time, y=value, col=variable)) +
22    ans = list()                                                  53        geom_line() +
23    time <- 0:(sampleSize)                                        54        xlab("Day") +
24    for (m in 1:3) ans[[m]] = data.frame("Time" = time)           55        ylab("Population") +
25 -   for (n in 1:runs) {                                          56        ggtitle(title)
26      print(n)                                                    57 - }
27      dat <- execSEIVRemote(n-1, sampleSize, "I", "DI+", "DD")    58
28      who <- c("I", "DI+", "DD")                                  59 - go <- function(runs=30, sampleSize=165) {
29 -     for (m in 1:3) {                                           60      data <- multiSEIV(runs, sampleSize)
30        ans[[m]] = cbind(ans[[m]], dat[,c(m+1)])                  61      list (
31        names(ans[[m]])[length(names(ans[[m]]))] = paste(who[m], "Run", n)   62        buildGraph(data[[1]], "Prevalence"),
32 -     }                                                          63        buildGraph(data[[2]], "Incidence"),
33 -   }                                                            64        buildGraph(data[[3]], "Daily Deaths")
34    ans                                                           65      )
35 - }                                                              66 - }
```

Figure B.5: Our M-SEIR can be treated as an R-package called "seiv" and run as such in conjunction with other packages, such as ggplot2 and reshape to conduct multiple simulations and then carry out data and statistical analyses of the simulation results. The code shown here was used to produce the plots illustrated in Fig. 3D & E.